<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T05:11:00Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:5808581" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:5808581</identifier>
        <datestamp>2018-07-31</datestamp>
        <setSpec>nihpa</setSpec>
        <setSpec>pmc-open</setSpec>
        <setSpec>manuscript</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-journal-id">0410462</journal-id>
              <journal-id journal-id-type="pubmed-jr-id">6011</journal-id>
              <journal-id journal-id-type="nlm-ta">Nature</journal-id>
              <journal-id journal-id-type="iso-abbrev">Nature</journal-id>
              <journal-title-group>
                <journal-title>Nature</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0028-0836</issn>
              <issn pub-type="epub">1476-4687</issn>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC5808581</article-id>
              <article-id pub-id-type="pmcid">PMC5808581</article-id>
              <article-id pub-id-type="pmc-uid">5808581</article-id>
              <article-id pub-id-type="pmid">29420467</article-id>
              <article-id pub-id-type="pmid">29420467</article-id>
              <article-id pub-id-type="doi">10.1038/nature25475</article-id>
              <article-id pub-id-type="manuscript">nihpa930367</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Article</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>HER kinase inhibition in patients with HER2- and HER3-mutant
cancers</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hyman</surname>
                    <given-names>David M.</given-names>
                  </name>
                  <xref ref-type="aff" rid="A1">1</xref>
                  <xref ref-type="author-notes" rid="FN1">*</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Piha-Paul</surname>
                    <given-names>Sarina A.</given-names>
                  </name>
                  <xref ref-type="aff" rid="A2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Won</surname>
                    <given-names>Helen</given-names>
                  </name>
                  <xref ref-type="aff" rid="A1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Rodon</surname>
                    <given-names>Jordi</given-names>
                  </name>
                  <xref ref-type="aff" rid="A3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Saura</surname>
                    <given-names>Cristina</given-names>
                  </name>
                  <xref ref-type="aff" rid="A3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Shapiro</surname>
                    <given-names>Geoffrey I.</given-names>
                  </name>
                  <xref ref-type="aff" rid="A4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Juric</surname>
                    <given-names>Dejan</given-names>
                  </name>
                  <xref ref-type="aff" rid="A5">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Quinn</surname>
                    <given-names>David I.</given-names>
                  </name>
                  <xref ref-type="aff" rid="A6">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Moreno</surname>
                    <given-names>Victor</given-names>
                  </name>
                  <xref ref-type="aff" rid="A7">7</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Doger</surname>
                    <given-names>Bernard</given-names>
                  </name>
                  <xref ref-type="aff" rid="A7">7</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mayer</surname>
                    <given-names>Ingrid A.</given-names>
                  </name>
                  <xref ref-type="aff" rid="A8">8</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Boni</surname>
                    <given-names>Valentina</given-names>
                  </name>
                  <xref ref-type="aff" rid="A9">9</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Calvo</surname>
                    <given-names>Emiliano</given-names>
                  </name>
                  <xref ref-type="aff" rid="A9">9</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Loi</surname>
                    <given-names>Sherene</given-names>
                  </name>
                  <xref ref-type="aff" rid="A10">10</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lockhart</surname>
                    <given-names>Albert C.</given-names>
                  </name>
                  <xref ref-type="aff" rid="A11">11</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Erinjeri</surname>
                    <given-names>Joseph P.</given-names>
                  </name>
                  <xref ref-type="aff" rid="A1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Scaltriti</surname>
                    <given-names>Maurizio</given-names>
                  </name>
                  <xref ref-type="aff" rid="A1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ulaner</surname>
                    <given-names>Gary A.</given-names>
                  </name>
                  <xref ref-type="aff" rid="A1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Patel</surname>
                    <given-names>Juber</given-names>
                  </name>
                  <xref ref-type="aff" rid="A1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Tang</surname>
                    <given-names>Jiabin</given-names>
                  </name>
                  <xref ref-type="aff" rid="A1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Beer</surname>
                    <given-names>Hannah</given-names>
                  </name>
                  <xref ref-type="aff" rid="A1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Selcuklu</surname>
                    <given-names>S. Duygu</given-names>
                  </name>
                  <xref ref-type="aff" rid="A1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hanrahan</surname>
                    <given-names>Aphrothiti J.</given-names>
                  </name>
                  <xref ref-type="aff" rid="A1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bouvier</surname>
                    <given-names>Nancy</given-names>
                  </name>
                  <xref ref-type="aff" rid="A1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Melcer</surname>
                    <given-names>Myra</given-names>
                  </name>
                  <xref ref-type="aff" rid="A1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Murali</surname>
                    <given-names>Rajmohan</given-names>
                  </name>
                  <xref ref-type="aff" rid="A1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Schram</surname>
                    <given-names>Alison M.</given-names>
                  </name>
                  <xref ref-type="aff" rid="A1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Smyth</surname>
                    <given-names>Lillian M.</given-names>
                  </name>
                  <xref ref-type="aff" rid="A1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Jhaveri</surname>
                    <given-names>Komal</given-names>
                  </name>
                  <xref ref-type="aff" rid="A1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Li</surname>
                    <given-names>Bob T.</given-names>
                  </name>
                  <xref ref-type="aff" rid="A1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Drilon</surname>
                    <given-names>Alexander</given-names>
                  </name>
                  <xref ref-type="aff" rid="A1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Harding</surname>
                    <given-names>James J.</given-names>
                  </name>
                  <xref ref-type="aff" rid="A1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Iyer</surname>
                    <given-names>Gopa</given-names>
                  </name>
                  <xref ref-type="aff" rid="A1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Taylor</surname>
                    <given-names>Barry S.</given-names>
                  </name>
                  <xref ref-type="aff" rid="A1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Berger</surname>
                    <given-names>Michael F.</given-names>
                  </name>
                  <xref ref-type="aff" rid="A1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Cutler</surname>
                    <given-names>Richard E.</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <xref ref-type="aff" rid="A12">12</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Xu</surname>
                    <given-names>Feng</given-names>
                  </name>
                  <xref ref-type="aff" rid="A12">12</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Butturini</surname>
                    <given-names>Anna</given-names>
                  </name>
                  <xref ref-type="aff" rid="A12">12</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Eli</surname>
                    <given-names>Lisa D.</given-names>
                  </name>
                  <xref ref-type="aff" rid="A12">12</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mann</surname>
                    <given-names>Grace</given-names>
                  </name>
                  <xref ref-type="aff" rid="A12">12</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Farrell</surname>
                    <given-names>Cynthia</given-names>
                  </name>
                  <xref ref-type="aff" rid="A12">12</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lalani</surname>
                    <given-names>Alshad S.</given-names>
                  </name>
                  <xref ref-type="aff" rid="A12">12</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bryce</surname>
                    <given-names>Richard P.</given-names>
                  </name>
                  <xref ref-type="aff" rid="A12">12</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Arteaga</surname>
                    <given-names>Carlos L.</given-names>
                  </name>
                  <xref ref-type="aff" rid="A8">8</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Meric-Bernstam</surname>
                    <given-names>Funda</given-names>
                  </name>
                  <xref ref-type="aff" rid="A2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Baselga</surname>
                    <given-names>José</given-names>
                  </name>
                  <xref ref-type="aff" rid="A1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Solit</surname>
                    <given-names>David B.</given-names>
                  </name>
                  <xref ref-type="aff" rid="A1">1</xref>
                </contrib>
              </contrib-group>
              <aff id="A1"><label>1</label>Memorial Sloan Kettering Cancer Center, New York, NY, USA</aff>
              <aff id="A2"><label>2</label>University of Texas, MD Anderson Cancer Center, Houston, TX,
USA</aff>
              <aff id="A3"><label>3</label>Vall d’Hebron University Hospital, Vall d’Hebron
Institute of Oncology (VHIO), Barcelona, Spain</aff>
              <aff id="A4"><label>4</label>Dana-Faber Cancer Institute, Boston, MA, USA</aff>
              <aff id="A5"><label>5</label>Massachusetts Hospital Cancer Center, Boston, MA, USA</aff>
              <aff id="A6"><label>6</label>USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA</aff>
              <aff id="A7"><label>7</label>START Madrid Fundación Jímenez Díaz, Madrid,
Spain</aff>
              <aff id="A8"><label>8</label>Vanderbilt-Ingram Cancer Center, Nashville, TN, USA</aff>
              <aff id="A9"><label>9</label>START Madrid, Centro Integral Oncológico Clara Campal
(CIOCC), Madrid, Spain</aff>
              <aff id="A10"><label>10</label>Peter MacCallum Cancer Centre, Melbourne, Australia</aff>
              <aff id="A11"><label>11</label>Washington University in St. Louis School of Medicine, St. Louis,
MO, USA</aff>
              <aff id="A12"><label>12</label>Puma Biotechnology Inc., Los Angeles, CA, USA</aff>
              <author-notes>
                <corresp id="FN1"><label>*</label><bold>Corresponding author:</bold> David Hyman, MD,
Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065,
USA. Telephone: (646) 888-4544. <email>hymand@mskcc.org</email></corresp>
              </author-notes>
              <pub-date pub-type="nihms-submitted">
                <day>4</day>
                <month>1</month>
                <year>2018</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>31</day>
                <month>1</month>
                <year>2018</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <day>08</day>
                <month>2</month>
                <year>2018</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>31</day>
                <month>7</month>
                <year>2018</year>
              </pub-date>
              <volume>554</volume>
              <issue>7691</issue>
              <fpage>189</fpage>
              <lpage>194</lpage>
              <!--elocation-id from pubmed: 10.1038/nature25475-->
              <permissions>
                <license>
                  <license-p>Users may view, print, copy, and download text and data-mine the
content in such documents, for the purposes of academic research, subject
always to the full Conditions of use:<ext-link ext-link-type="uri" xlink:href="http://www.nature.com/authors/editorial_policies/license.html#terms">http://www.nature.com/authors/editorial_policies/license.html#terms</ext-link></license-p>
                </license>
                <license license-type="permissions-link">
                  <license-p>Reprints and permissions information is available at <ext-link ext-link-type="uri" xlink:href="www.nature.com/reprints">www.nature.com/reprints</ext-link></license-p>
                </license>
              </permissions>
              <abstract>
                <title>Summary</title>
                <p id="P1">Somatic mutations of <italic>ERBB2</italic> (HER2) and
<italic>ERBB3</italic> (HER3) are found in a wide range of cancers.
Preclinical modelling suggests that a subset lead to constitutive HER2
activation, but most remain biologically uncharacterized. We sought to
prospectively define the biologic and therapeutic significance of known
oncogenic HER2 and HER3 mutations and variants of unknown biological
significance by conducting a multi-histology, genomically selected,
‘basket’ study utilizing the pan-HER kinase inhibitor neratinib
(SUMMIT; Clinicaltrials.gov NCT01953926). Efficacy in HER2-mutant cancers varied
as a function of both tumour type and mutant allele to a degree not predicted by
preclinical models, with the greatest activity seen in breast, cervical and
biliary cancers and with tumours harbouring kinase domain missense mutations.
This study demonstrates how a molecularly driven clinical trial can be used to
further refine our biological understanding of both characterized and novel
genomic alterations with potential broad applicability for advancing the
paradigm of genome-driven oncology.</p>
              </abstract>
            </article-meta>
          </front>
          <body>
            <sec sec-type="intro" id="S1">
              <title>Introduction</title>
              <p id="P2">Genomic profiling of human cancers has identified recurrent somatic mutations
of HER2 (<italic>ERBB2</italic>) and HER3 (<italic>ERBB3</italic>), typically
occurring in the absence of gene amplification<sup><xref rid="R1" ref-type="bibr">1</xref>–<xref rid="R3" ref-type="bibr">3</xref></sup>. Mutations
in HER2 are clustered in the extracellular, transmembrane, and kinase domains.
Unlike other mutant oncogenes, eg <italic>BRAF</italic> or <italic>KRAS</italic>, no
single mutant allele predominates and the precise distribution of mutations varies
by tumour type<sup><xref rid="R4" ref-type="bibr">4</xref></sup>. In contrast, HER3
mutations cluster primarily in the extracellular domain and to a lesser extent in
the kinase domain. Although HER2 and HER3 mutations are found in a wide variety of
cancers, their overall prevalence does not exceed 10% in any individual
tumour type and more typically the rate is &lt;5% for HER2 and
&lt;1% for HER3.</p>
              <p id="P3">Biological modelling has yielded conflicting findings addressing the
functional consequences of HER2 and HER3 mutations. Substantial data suggest that a
subset of these mutations lead to ligand-independent constitutive HER2 receptor
signalling and promotes oncogenesis<sup><xref rid="R5" ref-type="bibr">5</xref>–<xref rid="R7" ref-type="bibr">7</xref></sup>. The
mechanism of these oncogenic effects appears to differ by variant, with some causing
enhanced HER2 kinase activity and others receptor dimerization<sup><xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R8" ref-type="bibr">8</xref></sup>.
Mutations in HER3, which in its wild-type configuration has impaired kinase
function, appear to rely on wild-type HER2 to exert its oncogenic effects<sup><xref rid="R7" ref-type="bibr">7</xref></sup>. Most preclinical data exploring the
functional consequences of HER2 and HER3 mutations have been generated using
engineered models that overexpress the mutation and thus the results may be
confounded by the known oncogenic effects of HER2 overexpression. Further enforcing
the potential importance of this confounding variable, models of HER2 mutation
generated by gene-editing techniques have failed to demonstrate a malignant
phenotype in the absence of mutations in other oncogenes such as
<italic>PIK3CA</italic><sup><xref rid="R9" ref-type="bibr">9</xref></sup>.</p>
              <p id="P4">Given the significant diversity of HER2 and HER3 mutations, as well as the
challenge of generating preclinical models that recreate their true biology in human
cancers, we sought to define the therapeutic significance of HER2 and HER3 mutations
by conducting SUMMIT – a global, multicentre, multi-histology
‘basket’ study in patients with tumours harbouring these mutations
(<xref rid="F1" ref-type="fig">Extended Data Fig. 1</xref>). Patients were
treated with neratinib, an irreversible pan-HER tyrosine kinase inhibitor, which
potently inhibits the growth of HER2-mutant tumours in preclinical models<sup><xref rid="R5" ref-type="bibr">5</xref></sup>. Tumour tissue and plasma were
collected to facilitate the detailed genomic characterization of patients. Here, we
present the results of this study with a focus on the insights it provides into the
biological and therapeutic significance of HER2 and HER3 mutations in cancer
patients.</p>
            </sec>
            <sec sec-type="results" id="S2">
              <title>Results</title>
              <sec id="S3">
                <title>Patient and mutation characteristics</title>
                <p id="P5">Baseline patient demographics are shown in <xref rid="T5" ref-type="table">Table 1</xref> and <xref rid="T1" ref-type="table">Extended
Data Table 1</xref>. In total, 141 patients (125 with HER2-mutant tumours,
16 with HER3-mutant tumours) received neratinib. These patients were diagnosed
with one of 21 unique cancer types, the most common being breast, lung, bladder
and colorectal cancer (61% of patients treated). As has been seen in
other basket studies<sup><xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R11" ref-type="bibr">11</xref></sup>, we identified and enrolled a
number of orphan tumour types including cancers of the biliary tract, salivary
gland, small bowel and vagina, as well as extramammary Paget’s disease
(13% of all patients). Patients tended to be heavily pretreated with
approximately half having received ≥3 prior lines of systemic
therapy.</p>
                <p id="P6">Enrolled patients had 31 unique HER2 and 11 unique HER3 mutations (<xref rid="F2" ref-type="fig">Extended Data Fig. 2</xref>). The most frequent HER2
mutations were S310, L755, Y772_A775dup and V777 alleles. The HER2 kinase domain
was most commonly mutated (66%), followed by the extracellular
(26%) and transmembrane/juxtamembrane (8%) domains. The
anticipated relationships between the mutated HER2 domain and tumour type were
observed, with extracellular domain mutations predominant in bladder cancer,
kinase domain missense mutations in breast and colon cancer, and kinase domain
insertions in lung cancer<sup><xref rid="R4" ref-type="bibr">4</xref></sup>.
Missense mutations were the most common class of genomic alteration
(74%) followed by in-frame insertions (22%), the latter
exclusively affecting the kinase domain. Two patients harboured
insertions/deletions and one an in-frame kinase domain-retaining fusion
(<italic>GRB7-ERBB2</italic>)<sup><xref rid="R12" ref-type="bibr">12</xref>,<xref rid="R13" ref-type="bibr">13</xref></sup>. HER3
mutations were all missense variants and clustered in the extracellular
furin-like and receptor domains. In total, 87% (109/125) of HER2 and
75% (12/16) of HER3 mutations were at positions now known to be
mutational hotspots<sup><xref rid="R4" ref-type="bibr">4</xref></sup>. This
pattern of HER2 and HER3 mutations was comparable to the spectrum of
non-truncating HER2 and HER3 mutations observed in previously published genomic
landscape studies, including TCGA and ICGC<sup><xref rid="R4" ref-type="bibr">4</xref></sup>, although HER2 V777L and Y772_A755dup were more common
in our study cohort (13.6% vs 5.3% and 12.0% vs
2.7%, respectively, <xref rid="F3" ref-type="fig">Extended Data Fig.
3</xref>).</p>
              </sec>
              <sec id="S4">
                <title>Treatment outcomes</title>
                <p id="P7">When stratified by tumour type, we observed responses to neratinib in
patients with HER2-mutant breast, non-small-cell lung, cervical, biliary and
salivary cancers, which led to expanded enrollment in several of these tumour
types (<xref rid="F7" ref-type="fig">Fig. 1a</xref>, <xref rid="T1" ref-type="table">Extended Data Table 1</xref>). Neratinib exhibited the
greatest degree of activity in patients with breast cancer (n=25 total,
objective response rate at week 8 [ORR<sub>8</sub>] 32%,
95% confidence interval [CI] 15–54%)
with responses observed in patients with missense mutations involving the
extracellular and kinase domains, as well as insertions in the kinase domain.
All breast cancer patients were classified as HER2 negative (non-amplified) at
the time of enrolment per established guidelines<sup><xref rid="R14" ref-type="bibr">14</xref></sup>. Responses were observed in both
estrogen receptor (ER)+ (30%, 6/20) and ER- (40%, 2/5)
tumours. Overall, these breast cancer data are generally consistent with a prior
report<sup><xref rid="R15" ref-type="bibr">15</xref></sup>. In patients
with lung cancer (n=26), where exon 20 insertions predominate, we
observed only one objective response. Of note, HER2 exon 20 insertions are
paralogous of EGFR exon 20 insertions, which are resistant to first- and
second-generation EGFR tyrosine kinase inhibitors<sup><xref rid="R16" ref-type="bibr">16</xref></sup>. Interestingly, the only patient with
lung cancer to achieve a RECIST response had a kinase domain missense mutation
(L755S). Despite the low response rate, the median progression-free survival in
recurrent lung cancer was 5.5 months with 6 patients remaining on therapy for
greater than 1 year, which compares favourably to second-line chemotherapy and
immune checkpoint inhibitors<sup>176</sup>, suggesting that neratinib may still
be having a positive impact on the natural history of this disease. Responses
were also observed in biliary and cervical cancers, and enrolment is ongoing in
these cohorts to better define this activity. No responses were observed in
bladder cancer (n=16) or colorectal cancer (n=12), suggesting
lineage-dependent resistance to single-agent pan-HER kinase inhibition in these
tumour types. In summary, among the HER2-mutants cohorts, breast cancer met the
primary endpoint for efficacy, while lung, colorectal and bladder cancers did
not. For the remaining tumour-specific cohorts, enrolment is ongoing and they
have therefore not undergone final efficacy analysis. Despite preclinical data
suggesting that HER3 mutations can be oncogenic drivers, no responses to
neratinib were observed in patients with HER3-mutant tumours.</p>
                <p id="P8">When stratified by mutant allele, responses were observed in patients
with tumours harbouring HER2 S310, L755, V777, G778_P780dup and Y772_A775dup
mutations (<xref rid="F7" ref-type="fig">Fig. 1b</xref>). Among patients with
HER2 kinase domain hotspot missense mutations (n=42), responses were
noted in four unique tumour types (breast, biliary, lung and salivary gland). By
allele, we observed responses in several kinase domain mutants L755S
(n=4), V777L (n=4) and L869R (n=1). In patients with
HER2 hotspot extracellular domain mutations (S310, n=30), responses were
observed in breast, cervical and biliary cancers (n=1 for each), but not
in bladder cancer where these mutations predominate. Similarly, in patients with
HER2 exon 20 insertions (n=28), responses were observed in two patients
with breast cancer but none were seen in patients with lung cancer where this
class of alterations is most common. In exon 20 insertions, preservation of
glycine at the 770 position, which appears to facilitate binding of covalent HER
kinase inhibitors such as neratinib, did not predict for response as previously
suggested by preclinical modelling (<xref rid="F4" ref-type="fig">Extended Data
Fig. 4</xref>)<sup><xref rid="R18" ref-type="bibr">18</xref></sup>.
Similarly, the number of amino acids involved in the insertion did not appear to
predict outcome, with responses observed in patients with both 3 (G788_P780dup)
and 4 (Y722_A755dup) amino acid insertions. Finally, among the 15 patients with
HER2 mutations not known to be hotspots, only one responded to neratinib.
Interestingly, this response occurred in a patient with breast cancer and a
complex insertion/substitution (L755_E757delinsS) which, to our knowledge, has
not been observed previously. While this case illustrates that some patients may
be addicted to truly private oncogenic drivers (those arising in only a single
patient), it is also noteworthy that this insertion occurs in a domain that is
the target of recurrent insertions. The absence of clinical activity in the
remaining 14 patients with cancers with non-hotspot mutations suggests that
while the recurrence of a mutation in HER2 is insufficient to define it as
sensitizing to a HER2 kinase inhibitor, the absence of recurrence (ie mutations
that do not occur at hotspot positions) provides circumstantial evidence that
the alteration is unlikely to be a driver.</p>
                <p id="P9">While the overall numbers of patients in each subgroup preclude formal
statistical comparison, integrating efficacy, mutational and lineage data, we
observed that clinical benefit from neratinib therapy appeared to vary as a
function of both mutational and disease context (<xref rid="F8" ref-type="fig">Fig. 2</xref>). In tumour types sensitive to neratinib therapy, such as
breast, biliary and cervical cancers, responses were collectively observed
across all types and classes of HER2 mutations. In contrast, in lung cancer, a
tumour type that exhibits modest sensitivity to neratinib, response was limited
to a patient with a HER2 kinase domain missense mutation – a class of
mutations with greater <italic>in vitro</italic> sensitivity to
neratinib<sup><xref rid="R5" ref-type="bibr">5</xref></sup>. Finally, in
tumour types with intrinsic lineage-based resistance to neratinib, such as
bladder and colorectal cancers, RECIST responses were not observed regardless of
the HER2 mutation, type or class.</p>
              </sec>
              <sec id="S5">
                <title>Safety</title>
                <p id="P10">All patients received neratinib with mandatory anti-diarrhoeal
prophylaxis. With this regimen, the rate of grade 3 diarrhoea was 22%
(<xref rid="T2" ref-type="table">Extended Data Table 2</xref>), consistent
with previous experience<sup><xref rid="R19" ref-type="bibr">19</xref></sup>.
Among patients who developed grade 3 diarrhoea, the median time to onset was 10
days and the median duration of the diarrhoea episode 2 days. Patients were
typically managed with dose interruption and reduction, with only 2.8%
permanently discontinuing therapy due to diarrhoea. The remainder of adverse
events were low grade.</p>
              </sec>
              <sec id="S6">
                <title>Central confirmation of HER2 and HER3 mutations</title>
                <p id="P11">There is active debate within the cancer research community as to
whether central confirmation of mutational status before study entry is optimal
for determining trial eligibility for precision medicine studies. To define the
reproducibility of local mutational testing, DNA from archival formalin-fixed
paraffin-embedded tumour and plasma samples were re-sequenced (see Methods).
Thirty-three patients (26 with HER2-mutant, 7 with HER3-mutant) were excluded
from this concordance analysis because the local test used was the same as the
central tumour assay being evaluated. Of the remaining 99 patients with HER2
mutations, adequate material for tumour genomic testing was unobtainable for 26
patients. Overall, concordance in the remaining patients based on central tumour
and/or plasma sequencing was 95% (69/73), with 38 patients assessed by
tissue and plasma, 14 by tissue alone, and 21 by plasma alone. Central testing
identified one locally reported mutation (V773M) as a germline polymorphism and
this patient, with renal cell carcinoma, had progressive disease at first scan.
Central testing in the four cases where the HER2 mutation could not be confirmed
passed all quality-control metrics but in two patients was performed on material
collected ≥3 years after the tissue used for local testing, raising the
possibility that tumour heterogeneity played a role in the discordance. None of
the patients with discordant HER2 results responded to neratinib, and their
median progression-free survival was only 43 days (range: 5–58 days).
Among the 9 patients eligible for concordance testing with HER3 mutations,
tumour tissue was available for central sequencing in eight patients, and
overall concordance was 75% (6/8).</p>
              </sec>
              <sec id="S7">
                <title>Genomic modifiers of response</title>
                <p id="P12">Given the variability of treatment response, even among patients with
the same tumour lineage and HER2-mutant allele, we sought to identify additional
genomic modifiers of response through broader genomic characterization of
tumour-derived DNA (see Methods). First, we explored the relationship between
HER2 amplification and outcome, as this is a well-established predictor of
response to HER2-targeted therapies in patients lacking HER2 mutations. In
total, 17% of patients (15/86) had concurrent <italic>ERBB2</italic>
mutations and gene amplification. Amplifications preferentially targeted the
mutant allele locus (86%, 12/14 evaluable). Using a dichotomous
definition of clinical benefit (stable disease or partial response lasting
≥24 weeks), <italic>ERBB2</italic> amplification did not correlate with
outcome (p=0.50; <xref rid="F9" ref-type="fig">Fig. 3</xref>),
suggesting that in the presence of <italic>ERBB2</italic> mutations,
amplification may not confer additional sensitivity to irreversible HER kinase
inhibitors. We also explored the relationship of <italic>ERBB2</italic> mutation
clonality on outcomes. In the 74 patients with adequate material to allow
definitive assessment of <italic>ERBB2</italic> mutant clonality, the HER2
mutation was clonal in 95% (70/74, <xref rid="F5" ref-type="fig">Extended Data Fig. 5a</xref>). None of four patients with a subclonal HER2
mutation achieved clinical benefit.</p>
                <p id="P13">Hypothesizing that tumours with an increased tumour mutational burden
(TMB) might be more likely to acquire HER2 mutations without developing
oncogenic dependence (ie passenger mutations), we evaluated whether overall TMB
status affected outcome. Using a previously validated cut-off (≥13.8
non-synonymous mutations per megabase of DNA<sup>2</sup>), 20% of
patients (17/86) met criteria for high TMB. In total, 24% of patients
(16/66) without clinical benefit versus 5% of patients (1/20) with
benefit met criteria for high TMB, a trend that did not reach statistical
significance (p=0.10).</p>
                <p id="P14">Next, we evaluated whether the pattern of co-mutations affected clinical
benefit in the subset of patients where broader profiling was available
(n=86). In patients with HER2-mutant disease, coincident mutations in
TP53 and HER3 were enriched in patients with no clinical benefit (nominal
p=0.018 and p=0.064, respectively; <xref rid="F9" ref-type="fig">Fig. 3</xref>). While not significant after correcting for multiple
hypothesis testing potentially due to the relatively small sample size, it is
noteworthy that no patients with clinical benefit possessed co-mutation of HER2
and HER3. Concurrent mutation of these genes was observed in multiple cancer
types (breast n=3, bladder n=2, gastroesophageal n=2,
colorectal n=1 and pancreatic n=1) and involved a variety of
unique HER2 and HER3 mutations (n=8 and n=9, respectively).
Expanding our analysis to genomic activation at the pathway level, we identified
somatic mutations of known oncogenic potential and grouped them by those
involving the RTKs/RAS/RAF and PIK3CA/AKT/MTOR pathways, and cell cycle
checkpoints (<xref rid="F5" ref-type="fig">Extended Data Fig. 5b</xref>). In
this analysis, aberrations in cell cycle checkpoints were associated with lack
of clinical benefit (p=0.043), while activation of RTK/RAS/RAF also
trended towards a worse outcome (p=0.060). The association between the
cell cycle pathway and lack of clinical benefit appears to be primarily driven
by TP53 mutations, losing significance upon removal of TP53 mutations
(p=0.769). Interestingly, activation of the PI3K/AKT/mTOR pathway, an
established negative predictor of response to HER2-targeted therapy in
HER2-amplified breast cancer<sup><xref rid="R20" ref-type="bibr">20</xref>–<xref rid="R22" ref-type="bibr">22</xref></sup>, did
not adversely affect the likelihood of clinical benefit (p=0.753). It is
possible that the clinical impact of concurrent gene/pathway activation may vary
by tumour type, and future disease-specific studies are needed to better define
these associations. Although these were exploratory analyses that will require
confirmation, our results suggest that concurrent activation of specific genes
as well as pathways may act as an additional modifier of response beyond cancer
type and specific HER2 mutant allele.</p>
              </sec>
            </sec>
            <sec sec-type="discussion" id="S8">
              <title>Discussion</title>
              <p id="P15">The ability to comprehensively profile cancer at the point of care has made
possible the opportunity to personalize therapy for each patient based on the
compendium of genomic alterations identified<sup><xref rid="R23" ref-type="bibr">23</xref></sup>. Despite the promise of this approach, implementing this
paradigm in clinical practice has been hampered by significant gaps in knowledge
regarding the biological and clinical significance of the majority of genomic
variants identified<sup><xref rid="R24" ref-type="bibr">24</xref></sup>. This
challenge is exemplified by the marked diversity and wide distribution of HER2 and
HER3 mutations in human cancers, as well as by the difficulty of generating
preclinical models of these mutations that faithfully recreate their biology in
patients. SUMMIT provides the first comprehensive dataset on the clinical
actionability of HER2 and HER3 mutations. We found that HER2 mutations are
associated with HER2-dependence in a subset of patients with HER2 mutant tumors, but
that response to HER kinase inhibition varies a function of the individual mutant
variant, the tumour types as well as the pattern of co-mutations present.</p>
              <p id="P16">Although we identified promising preliminary activity for neratinib in
breast, biliary and cervical cancers, the response rate in these tumours was still
lower than with approved therapies targeting oncogenic alterations in
<italic>EGFR</italic>, <italic>ALK</italic>, <italic>ROS1</italic>, and
<italic>BRAF</italic>. The low response rate in lung cancer, where HER2
mutations exhibit mutually exclusivity of other known drivers<sup><xref rid="R25" ref-type="bibr">25</xref></sup>, is also striking and may in part reflect a
lower potency of neratinib inhibition in Y772_A775dup compared to others insertions
or missense mutants.<sup><xref rid="R18" ref-type="bibr">18</xref></sup> It is
noteworthy that successfully targeting HER2 activation in other contexts has
historically necessitated drug combinations. For example, single-agent trastuzumab
has a response rate of only ~20% in <italic>ERBB2</italic>-amplified
breast cancer<sup><xref rid="R26" ref-type="bibr">26</xref>,<xref rid="R27" ref-type="bibr">27</xref></sup>. In contrast, overall survival in
<italic>ERBB2</italic>-amplified breast and gastroesophageal cancers is markedly
improved by adding trastuzumab to chemotherapy<sup><xref rid="R28" ref-type="bibr">28</xref>,<xref rid="R29" ref-type="bibr">29</xref></sup>. More recently,
intensification of HER2 inhibition through combination of two HER-targeted agents
has been shown to result in synergistic efficacy in patients with
<italic>ERBB2</italic>-amplified breast<sup><xref rid="R30" ref-type="bibr">30</xref>–<xref rid="R32" ref-type="bibr">32</xref></sup> or
colorectal<sup><xref rid="R33" ref-type="bibr">33</xref>,<xref rid="R34" ref-type="bibr">34</xref></sup> cancers, as well as in HER2-mutant
colorectal cancer xenografts<sup><xref rid="R6" ref-type="bibr">6</xref></sup>.
Cumulatively, these data suggest that combining neratinib with another HER-targeted
therapy is a rational next step, and SUMMIT has been amended to evaluate this
approach in multiple HER2-mutant tumour types.</p>
              <p id="P17">SUMMIT represents a continued evolution in the design of basket studies,
which enrol patients on the basis of qualifying mutations rather than tumour type.
The initial generation of these studies focused on evaluating individual somatic
mutations that were already clinically validated in one cancer (eg
<italic>BRAF</italic> V600 in melanoma) in other tumour types<sup><xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R35" ref-type="bibr">35</xref></sup>. More recently, basket studies have been used to generate
initial or even practice-changing clinical data of truly novel genomic biomarkers,
especially when these genomic alterations occur at low frequency across a wide
distribution of cancer types<sup><xref rid="R11" ref-type="bibr">11</xref>,<xref rid="R36" ref-type="bibr">36</xref>,<xref rid="R37" ref-type="bibr">37</xref></sup>. SUMMIT extends this concept one step further by
demonstrating for the first time how a single study can be used to simultaneously
evaluate a range of individual variants in HER2 and HER3, each with varying degrees
of prior biologic characterization. This permissive enrolment strategy allowed us to
treat patients harbouring mutations that at the time of enrolment had not been
characterized preclinically as gain of function but were either recurrent or
paralogous to known activating mutations in homologous genes. For example, patients
with previously uncharacterized HER2 variants, such as V697, D769N, and L869R, were
included in this manner and responded to treatment, thus providing initial clinical
proof-of-concept that these mutations confer a gain-of-function phenotype even
before formal biologic characterization. The approach of pairing a permissive
enrolment strategy with allele prioritization based on recurrence, paralogy and
other readily computable features has potentially broad applicability to
implementing genomic-driven oncology<sup><xref rid="R24" ref-type="bibr">24</xref></sup>. This strategy will take on even greater importance as clinical
testing moves from targeted sequencing to whole exome or even whole genome
sequencing, techniques that will allow for evaluation of an even greater number of
therapeutic hypothesis but will also exponentially grow the number of
uncharacterized alleles we routinely identify.</p>
              <p id="P18">SUMMIT provides additional insights into the conduct of molecularly driven
oncology studies. Our ability to understand the complex interactions between tumour
lineage, individual HER2 variant, and response to neratinib was only possible
because of the relatively large size of this study (n=141). By comparison,
many of the ‘master/umbrella’ protocols currently underway are
designed to enroll a maximum of 30–40 patients into each genomically defined
treatment arm. Our experience suggests that many of studies of this size may be
inadequately powered to identify the subgroups with true efficacy, assuming that
most genomic alterations will not predict for tumour-type agnostic efficacy. SUMMIT
also demonstrates the feasibility of enrolling patients based on local testing with
patients enrolled on the basis of 30 unique sequencing assays performed in 25
different laboratories. Despite this, concordance on retrospective central review
was extremely high (96%).</p>
              <p id="P19">An important impediment to progress in oncology has been the limited
availability of preclinical model systems that accurately recreate the complex
biology of human cancer. While significant strides have been made, the wide-scale
profiling of cancer in the clinic provides the potentially transformative
opportunity to rapidly interrogate cancer biology at the bedside in a manner
previously only possible at the bench. Here, we demonstrate how this opportunity can
be leveraged to probe the biology of a diverse set of HER2 and HER3 mutations across
a variety of solid tumours through pharmacological HER kinase inhibition in
patients. In doing so, we found that response to pharmacological inhibition was
based on the characteristics of both tumour type and genomic variant to a degree
that was not predicted by established preclinical models. In summary, SUMMIT
demonstrates how the clinical trial can become an important tool in refining our
understanding of the biological dependencies in human cancers.</p>
            </sec>
            <sec sec-type="methods" id="S9">
              <title>Methods</title>
              <sec id="S10">
                <title>Patients</title>
                <p id="P20">Eligible patients had histologically confirmed advanced solid tumours
harbouring HER2 or HER3 mutations, an Eastern Cooperative Oncology Group (ECOG)
performance score of 0-2 and an unlimited number of prior therapies. Patients
with prior exposure to HER kinase inhibitors and unstable brain metastases were
excluded. HER2 and HER3 mutations were determined by local tumour testing as
routinely performed or ordered by each participating site. In total, 85%
(120/141) of enrolled patients were identified by next-generation sequencing
assays. In 81% of cases (97/120), the next-generation sequencing assay
included full exon coverage for <italic>ERBB2</italic> or
<italic>ERBB3</italic>, while in 19% (23/120) of cases only select exons
or hotspots were included in the assay design. The remaining 15%
(21/141) of patients were enrolled via RT-PCR, Sanger, pyrosequencing, or mass
spectrometry-based sequencing methods. The study was approved by the
institutional review board or independent ethics committee at each site and
complied with the International Ethical Guidelines for Biomedical Research
Involving Human Subjects, Good Clinical Practice guidelines, the Declaration of
Helsinki, and local laws. Written informed consent was obtained from all
participants.</p>
              </sec>
              <sec id="S11">
                <title>Study design, treatment and endpoints</title>
                <p id="P21">This was a multi-cohort basket study of patients with solid tumours
harbouring HER2 and HER3 mutations. Patients with HER2-mutant tumours were
enrolled into one of several disease-specific cohorts or an
“Other” cohort for tumour types not otherwise specified; all
patients with HER3-mutant tumours were enrolled to one cohort. Patients known to
harbour both HER2 and HER3 mutations at the time of enrolment were assigned to
the HER2-mutant cohort. Patients were treated with neratinib 240 mg daily on a
continuous basis with mandatory loperamide prophylaxis during cycle 1. The
primary endpoint was ORR<sub>8</sub>, as assessed by investigators according to
Response Evaluation Criteria in Solid Tumors (RECIST; version 1.1). Secondary
endpoints included best overall response, progression-free survival, overall
survival and safety. Patients who were not evaluable by RECIST were permitted to
enrol and were evaluated for response by <sup>18</sup>F-fluorodeoxyglucose
positron-emission tomography (PET) according to a modified version of the
original PET Response Criteria in Solid Tumors (PERCIST; version1.0)<sup><xref rid="R38" ref-type="bibr">38</xref></sup>, referred to here as PET
Response Criteria (PRC, <xref rid="T3" ref-type="table">Extended Data Table
3</xref>).</p>
              </sec>
              <sec id="S12">
                <title>Assessments</title>
                <p id="P22">Disease assessments with computed tomography (CT), magnetic resonance
imaging or PET/CT (for those evaluated by PRC) were performed at baseline and
then every 8 weeks until disease progression, death or withdrawal. Adverse
events were graded by the investigator according to the Common Terminology
Criteria for Adverse Events (version 4.0) until day 28 after discontinuation of
study treatment.</p>
              </sec>
              <sec id="S13">
                <title>Genomic biomarker studies</title>
                <p id="P23">All samples were assigned anonymized identifiers by the study sponsor
based on the order of study enrolment. Both tumour DNA and tumour-derived
cell-free (cf)DNA in plasma were collected with the goals of confirming locally
reported HER2/3 mutations as well as evaluating how <italic>ERBB2/3</italic>
copy number and clonality as well as co-mutational pattern affected outcome.
Collection of archival tumour and plasma samples was mandatory for all patients.
Next-generation sequencing was performed utilizing targeted sequencing of
pretreatment DNA from formalin-fixed paraffin-embedded tumour and matched blood
specimens (preferentially) and cfDNA (if tumour was not available or was
inadequate). A custom single-gene ERBB2 capture next-generation sequencing test
was also performed on pretreatment cfDNA in a subset of patients with
HER2-mutant disease.</p>
              </sec>
              <sec id="S14">
                <title>Central sequencing confirmation</title>
                <p id="P24">For patients with adequate material, DNA from formalin-fixed
paraffin-embedded (n=91) or tumour-derived cell-free DNA from plasma
(n=15) and matched germline DNA (n=102) underwent targeted
next-generation sequencing assay using Memorial Sloan Kettering-Integrated
Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)<sup><xref rid="R39" ref-type="bibr">39</xref></sup>, producing an average of 738-fold
coverage per tumour (range: 253–1383). Briefly, this assay utilizes a
hybridization-based exon capture designed to capture all protein-coding exons
and select introns of oncogenes, tumour suppressor genes and key members of
pathways that may be actionable by targeted therapies. In this study, either 341
(n=18) or 410 (n=88) key cancer-associated genes were used
(<xref ref-type="supplementary-material" rid="SD1">Supplementary
Information</xref>). Sequencing data were analysed as previously described
to identify somatic single-nucleotide variants, small insertions and deletions,
copy number alterations and structural arrangements<sup><xref rid="R40" ref-type="bibr">40</xref></sup>. Additionally, hotspot alterations were
identified using an adaptation of a previously described method<sup><xref rid="R41" ref-type="bibr">41</xref></sup> applied to a cohort of 24,592
sequenced human cancers<sup><xref rid="R42" ref-type="bibr">42</xref></sup>. For
gene level analysis, select genes within our targeted 341/410 MSK-IMPACT panel
involved in the RTK/RAS/RAF, PIK3CA/AKT/MTOR, and cell cycle checkpoint pathways
were selected using the KEGG pathway database<sup><xref rid="R43" ref-type="bibr">43</xref></sup>. For pathway level analysis, only
potentially oncogenic alterations in the selected genes were included and
determined to be oncogenic by OncoKB (version September 2017), a curated
knowledge base of the oncogenic effects and treatment implications of mutations
and cancer genes (oncokb.org<sup><xref rid="R44" ref-type="bibr">44</xref></sup>).</p>
              </sec>
              <sec id="S15">
                <title>HER2 amplification and clonality analysis</title>
                <p id="P25">For patients in the HER2-mutant arm with MSK-IMPACT sequencing data
(with matched germline DNA, n=74), the Fraction and Allele-Specific Copy
Number Estimates from Tumour Sequencing (FACETS) algorithm (version 0.3.9) was
used to estimate tumour purity and ploidy, total and allele-specific copy
number<sup><xref rid="R45" ref-type="bibr">45</xref></sup>. Tumour
samples with purity &lt;20% were excluded from the analysis. Focal
HER2 amplifications for tumours with MSK-IMPACT and FACETS data were inferred
using the following criteria: fold change ≥1.5 (MSK-IMPACT tumour:normal
sequencing coverage ratio) and total HER2 copy number ≥4 copies
(FACETS-derived total copy number). To infer clonality of each HER2 mutation,
cancer cell fractions (CCFs) were estimated with 95% confidence
intervals by integrating FACETS-derived joint segmentation and MSK-IMPACT
mutation data as input into the ABSOLUTE algorithm<sup><xref rid="R46" ref-type="bibr">46</xref></sup> (version 1.0.6). Mutations were
classified as either clonal or subclonal based on the following criteria: clonal
if the estimated CCF &gt;0.85, otherwise subclonal. For patients with HER2
amplification, the mutation copy number (mutation multiplicity) was calculated
as previously described<sup><xref rid="R47" ref-type="bibr">47</xref></sup> to
infer amplification of the mutant allele when the mutation multiplicity was
greater than half of the total HER2 copy number.</p>
              </sec>
              <sec id="S16">
                <title>Tumour mutational burden and microsatellite instability</title>
                <p id="P26">Tumour mutational burden (TMB), defined as the number of non-synonymous
mutations per megabase, was calculated for patients with MSK-IMPACT sequencing
data (n=106)<sup><xref rid="R6" ref-type="bibr">6</xref></sup>.
Microsatellite instability (MSI) was assessed for patients with HER2-mutant
tumours with matched germline DNA sequencing data (n=89) using an
orthogonal bioinformatics tool, MSIsensor<sup><xref rid="R48" ref-type="bibr">48</xref></sup>. Additionally, mutations were decomposed into the
thirty constituent mutational signatures as described previously<sup><xref rid="R49" ref-type="bibr">49</xref></sup>. Briefly, MSIsensor scores
&lt;10 were classified as microsatellite stable and &gt;10 were
considered MSI-High using a previously validated cut-off score<sup><xref rid="R50" ref-type="bibr">50</xref></sup>. Those with a MSIsensor score
of &lt;10 but having evidence of a dominant mismatch repair mutational
signature were also considered MSI<sup><xref rid="R45" ref-type="bibr">45</xref>,<xref rid="R49" ref-type="bibr">49</xref></sup>.</p>
              </sec>
              <sec id="S17">
                <title>Statistical analysis</title>
                <p id="P27">For each HER2-mutant tumour type and the HER3-mutant cohort, a Simon
optimal two-stage design with a true ORR<sub>8</sub> ≤10% was
considered unacceptable (null hypothesis) whereas a true ORR<sub>8</sub>
≥30% (alternative hypothesis) merited further study. Efficacy in
each cohort was analysed independently and the study was not designed to
formally compare efficacy across cohorts. All patients who received at least one
dose of neratinib were included in the safety and efficacy cohorts. All data
reflect an interim data-cut taken on 10 Mar 2017 from patients enrolled up to 16
Dec 2016 (<xref rid="F6" ref-type="fig">Extended Data Fig. 6</xref>). Most
patients were off therapy at the time of data analysis (<xref rid="T4" ref-type="table">Extended Data Table 4</xref>). Progression-free survival
was estimated using the Kaplan-Meier method. The study is registered at
Clinicaltrials.gov, NCT01953926. Individual associations among genomic changes
and response were assessed by either Fisher’s exact or chi-squared tests
(where appropriate) and corrected for multiple hypothesis testing using
Benjamini-Hochberg correction.</p>
                <p id="P28">Chi-squared or Fisher’s exact tests were performed to compare
gene-level and pathway-level associations between the dichotomous clinical
benefit groups. P-values were corrected for multiple hypothesis testing using
Benjamini-Hochberg correction. HER2 and HER3 lollipop distribution plots were
generated using ProteinPaint<sup><xref rid="R51" ref-type="bibr">51</xref></sup>. All other figures were generated using R software (<ext-link ext-link-type="uri" xlink:href="http://www.R-project.org/">http://www.R-project.org/</ext-link>).</p>
              </sec>
              <sec id="S18">
                <title>Data availability</title>
                <p id="P29">All datasets generated during and/or analysed during the current study,
including patient-level clinical data as well as all sequencing data have been
deposited and are publically available in the cBioPortal for Cancer Genomics
under the accession code “SUMMIT, Nature, 2018” (<ext-link ext-link-type="uri" xlink:href="http://www.cbioportal.org/study?id=summit_2018">http://www.cbioportal.org/study?id=summit_2018</ext-link>). All
figure source data are also provided at <ext-link ext-link-type="uri" xlink:href="www.nature.com/nature">www.nature.com/nature</ext-link>.</p>
              </sec>
            </sec>
            <sec id="S19">
              <title>Extended Data</title>
              <fig id="F1" orientation="portrait" position="anchor">
                <label>Extended Data Figure 1</label>
                <caption>
                  <title>Design of SUMMIT study</title>
                  <p id="P30">Five tumour-specific HER2 (<italic>ERBB2</italic>)-mutant cohorts
were pre-specified (endometrial, gastroesophageal, ovarian, colorectal and
bladder/urinary tract). In addition, a sixth “Solid tumour
(NOS)” HER2-mutant cohort allowed for enrollment of patients with
any other cancer types. A sufficient number of patients with breast,
cervical, biliary and lung cancer were enrolled in the “Solid
tumours (NOS)” cohort to permit independent efficacy analysis using
the same design as the pre-specified cohorts. Patients with HER3
(<italic>ERBB3</italic>)-mutant tumours were enrolled in a HER3-specific
cohort regardless of tumour type.</p>
                  <p id="P31">CBR, clinical benefit rate; cfDNA, cell-free
[tumour] DNA; CI, confidence interval; FFPE, formalin-fixed
paraffin-embedded; MSKCC, Memorial Sloan Kettering Cancer Center;
MSK-IMPACT, Memorial Sloan Kettering-Integrated Mutation Profiling of
Actionable Cancer Targets; NGS, next-generation sequencing; NOS, not
otherwise specified; ORR, objective response rate; ORR<sub>8</sub>,
objective response rate at week 8; PET, positron-emission tomography; PFS,
progression-free survival; RECIST, Response Evaluation Criteria in Solid
Tumors.</p>
                </caption>
                <graphic xlink:href="nihms930367f1"/>
              </fig>
              <fig id="F2" orientation="portrait" position="anchor">
                <label>Extended Data Figure 2</label>
                <caption>
                  <title>Distribution of a) 125 HER2 and b) 16 HER3 mutations positioned by their
amino acid co-ordinates across the respective protein domains</title>
                  <p id="P32">Each unique mutation is represented by a circle, with the circle
size and number representing the frequency, and coloured to show the
mutation class as indicated in the legend. The corresponding amino acid
change and common hotspot mutations (shown in pink) are labelled next to the
circles.</p>
                </caption>
                <graphic xlink:href="nihms930367f2"/>
              </fig>
              <fig id="F3" orientation="portrait" position="anchor">
                <label>Extended Data Figure 3</label>
                <caption>
                  <title>Spectrum of HER2 and HER3 Mutations Observed in Neratinib Study versus
TCGA, ICGC, and other Public Datasets</title>
                  <p id="P33">Distribution of a) HER2 and b) HER3 mutations observed across our
cohort in comparison to the spectrum of HER2 and HER3 mutations (reflected
lollipop) from publically available datasets (TCGA, ICGC, other published
studies).</p>
                </caption>
                <graphic xlink:href="nihms930367f3"/>
              </fig>
              <fig id="F4" orientation="portrait" position="anchor">
                <label>Extended Data Figure 4</label>
                <caption>
                  <title>Distribution and outcome of 28 <italic>HER2</italic> exon 20
insertions</title>
                  <p id="P34">a) Percent best change and PFS plots corresponding to each type of
exon 20 insertion (colour coded by synonymous amino acid change). Three
cases with no change are indicated in colour-coded circles above the x-axis.
b) Zoomed-in schematic of all exon 20 insertions positioned by their amino
acid co-ordinates and frequencies. c) Five unique types of exon 20
insertions observed in the study with the resulting full amino acid
sequences (insertion indicated in red).</p>
                  <p id="P35">PET, positron-emission tomography; PFS, progression-free survival;
RECIST, Response Evaluation Criteria in Solid Tumors.</p>
                </caption>
                <graphic xlink:href="nihms930367f4"/>
              </fig>
              <fig id="F5" orientation="portrait" position="anchor">
                <label>Extended Data Figure 5</label>
                <caption>
                  <title>Genomic modifiers of response and outcome by treatment duration</title>
                  <p id="P36">a) Cancer cell fractions with 95% confidence intervals and
clonality status of all HER2 mutations in 74 patients with sufficient
sequencing data ordered by increasing clinical benefit (weeks on therapy).
b) Comparison of the percent activation of known oncogenic alterations in
the three pathways between the patients of clinical benefit (n=20,
biologically independent samples) and no benefit (n=66, biologically
independent samples). Nominal Fisher’s p-values shown.</p>
                </caption>
                <graphic xlink:href="nihms930367f5"/>
              </fig>
              <fig id="F6" orientation="portrait" position="anchor">
                <label>Extended Data Figure 6</label>
                <caption>
                  <p id="P37">SUMMIT Consort Diagram.</p>
                </caption>
                <graphic xlink:href="nihms930367f6"/>
              </fig>
              <table-wrap id="T1" position="anchor" orientation="portrait">
                <?scale 60?>
                <label>Extended Data Table 1</label>
                <caption>
                  <p id="P38">Patient demographics and efficacy by cohort CI, confidence interval;
ORR, objective response rate; PFS, progression-free survival.</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <thead>
                    <tr>
                      <th valign="bottom" rowspan="3" align="left" colspan="1">Characteristic</th>
                      <th colspan="10" valign="bottom" align="center" rowspan="1">HER2</th>
                      <th valign="bottom" align="center" rowspan="1" colspan="1">HER3</th>
                    </tr>
                    <tr>
                      <th colspan="11" valign="bottom" align="left" rowspan="1">
                        <hr/>
                      </th>
                    </tr>
                    <tr>
                      <th valign="bottom" align="center" rowspan="1" colspan="1">Breast<break/>(n=25)</th>
                      <th valign="bottom" align="center" rowspan="1" colspan="1">Lung<break/>(n=26)</th>
                      <th valign="bottom" align="center" rowspan="1" colspan="1">Bladder<break/>(n=16)</th>
                      <th valign="bottom" align="center" rowspan="1" colspan="1">Colorectal<break/>(n=12)</th>
                      <th valign="bottom" align="center" rowspan="1" colspan="1">Biliary
tract<break/>(n=9)</th>
                      <th valign="bottom" align="center" rowspan="1" colspan="1">Cervical<break/>(n=5)</th>
                      <th valign="bottom" align="center" rowspan="1" colspan="1">Endometrial<break/>(n=7)</th>
                      <th valign="bottom" align="center" rowspan="1" colspan="1">Gastro
esophageal<break/>(n=5)</th>
                      <th valign="bottom" align="center" rowspan="1" colspan="1">Ovarian<break/>(n=4)</th>
                      <th valign="bottom" align="center" rowspan="1" colspan="1">NOS<break/>(n=16)</th>
                      <th valign="bottom" align="center" rowspan="1" colspan="1">NOS<break/>(n=16)</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">Median (range), years</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">57.0 (37–80)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">62.0 (46–74)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">65.0 (48–83)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">65.0 (30–81)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">66.0 (57–78)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">49.0 (42–56)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">57.0 (54–74) 5</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">67.0 (36–70)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">56.5 (38–58)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">59.0 (32–80)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">66.0 (39–82)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1"> &lt;65 years, n
(%)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">19 (76.0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">18 (69.2)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">8 (50.0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">6 (50.0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">2 (22.2)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">5 (100)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">(71.4)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">1 (20.0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">4 (100)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">13 (81.3)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">7 (43.8)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1"> ≥65 years, n
(%)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">6 (24.0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">8 (30.8)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">8 (50.0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">6 (50.0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">7 (77.8)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">2 (28.6)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">4 (80.0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">3 (18.8)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">9 (56.3)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">Sex, n (%)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1"/>
                      <td valign="top" align="center" rowspan="1" colspan="1"/>
                      <td valign="top" align="center" rowspan="1" colspan="1"/>
                      <td valign="top" align="center" rowspan="1" colspan="1"/>
                      <td valign="top" align="center" rowspan="1" colspan="1"/>
                      <td valign="top" align="center" rowspan="1" colspan="1"/>
                      <td valign="top" align="center" rowspan="1" colspan="1"/>
                      <td valign="top" align="center" rowspan="1" colspan="1"/>
                      <td valign="top" align="center" rowspan="1" colspan="1"/>
                      <td valign="top" align="center" rowspan="1" colspan="1"/>
                      <td valign="top" align="center" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1"> Female</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">24 (96.0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">17 (65.4)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">3 (18.8)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">6 (50.0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">5 (55.6)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">5 (100)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">7 (100)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">2 (40.0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">4 (100)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">7 (43.8)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">12 (75.0)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1"> Male</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">1 (4.0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">9 (34.6)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">13 (81.3)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">6 (50.0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">4 (44.4)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">3 (60.0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">9 (56.3)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">4 (25.0)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">ECOG PS, n (%)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1"/>
                      <td valign="top" align="center" rowspan="1" colspan="1"/>
                      <td valign="top" align="center" rowspan="1" colspan="1"/>
                      <td valign="top" align="center" rowspan="1" colspan="1"/>
                      <td valign="top" align="center" rowspan="1" colspan="1"/>
                      <td valign="top" align="center" rowspan="1" colspan="1"/>
                      <td valign="top" align="center" rowspan="1" colspan="1"/>
                      <td valign="top" align="center" rowspan="1" colspan="1"/>
                      <td valign="top" align="center" rowspan="1" colspan="1"/>
                      <td valign="top" align="center" rowspan="1" colspan="1"/>
                      <td valign="top" align="center" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1"> 0</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">7 (28.0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">11 (42.3)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">6 (37.5)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">5 (41.7)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">2 (22.2)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">1 (20.0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">2 (28.6)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">3 (18.8)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">1 (6.3)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1"> 1</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">17 (68.0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">14 (53.8)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">10 (62.5)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">7 (58.3)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">6 (66.7)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">4 (80.0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">5 (71.4)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">5 (100)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">4 (100)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">11 (68.8)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">12 (75.0)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1"> 2</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">1 (4.0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">1 (3.8)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">1 (11.1)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">2 (12.5)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">3 (18.8)’</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">Prior systemic lines, n (%)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">1 (3.8)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">1 (6.3)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">1 (11.1)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">1 (6.3)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1"> None</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">3 (12.0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">12 (46.2)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">2 (12.5)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">4 (33.3)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">3 (33.3)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">1 (14.3)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">2 (40.0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">6 (37.5)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">1 (6.3)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1"> 1</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">2 (8.0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">6 (23.1)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">9 (56.3)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">3 (25.0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">2 (22.2)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">3 (60.0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">2 (28.6)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">1 (20.0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">2 (12.5)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">11 (68.8)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1"> 2</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">20 (80.0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">7 (26.9)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">4 (25.0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">5 (41.7)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">3 (33.3)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">2 (40.0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">4 (57.1)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">2 (40.0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">4 (100)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">7 (43.8)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">4 (25.0)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1"> ≥3</td>
                      <td valign="top" align="center" rowspan="1" colspan="1"/>
                      <td valign="top" align="center" rowspan="1" colspan="1"/>
                      <td valign="top" align="center" rowspan="1" colspan="1"/>
                      <td valign="top" align="center" rowspan="1" colspan="1"/>
                      <td valign="top" align="center" rowspan="1" colspan="1"/>
                      <td valign="top" align="center" rowspan="1" colspan="1"/>
                      <td valign="top" align="center" rowspan="1" colspan="1"/>
                      <td valign="top" align="center" rowspan="1" colspan="1"/>
                      <td valign="top" align="center" rowspan="1" colspan="1"/>
                      <td valign="top" align="center" rowspan="1" colspan="1"/>
                      <td valign="top" align="center" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">Median time from metastasis to enrolment,
years (range)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">2.64<break/>(0.1–15.0)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.83<break/>(0.1–3.1)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.69<break/>(0.2–2.3)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">1.14<break/>(0.0–2.7)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">1.00<break/>(0.0–2.8)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">1.40<break/>(0.3–4.5)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.43<break/>(0.2–4.4)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0.80<break/>(0.4–4.3)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">7.54<break/>(1.1–7.7)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">1.35<break/>(0.0–5.4)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">1.13<break/>(0.3–4.5)</td>
                    </tr>
                    <tr>
                      <td colspan="12" valign="bottom" align="left" rowspan="1">
                        <hr/>
                      </td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">Outcome</td>
                      <td colspan="10" valign="top" align="center" rowspan="1">HER2</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">HER3</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td colspan="11" valign="bottom" align="center" rowspan="1">
                        <hr/>
                      </td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="center" rowspan="1" colspan="1">Breast<break/>(n=25)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">Lung<break/>(n=26)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">Bladder<break/>(n=16)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">Colorectal<break/>(n=12)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">Biliary tract<break/>(n=9)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">Cervical<break/>(n=5)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">Endometrial<break/>(n=7)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">Gastroesophageal<break/>(n=5)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">Ovarian<break/>(n=4)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">NOS<break/>(n=16)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">NOS<break/>(n=16)</td>
                    </tr>
                    <tr>
                      <td colspan="12" valign="bottom" align="left" rowspan="1">
                        <hr/>
                      </td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">ORR at week 8, n
(%)<break/>[95% CI]</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">8
(32.0)<break/>[14.9–53.5]</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">1
(3.8)<break/>[0.1–19.6]</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0
(0.0)<break/>[0.0–20.6]</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0
(0.0)<break/>[0.0–26.5]</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">2
(22.2)<break/>[2.8–60.0]</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">1
(20.0)<break/>[0.5–71.6]</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0
(0.0)<break/>[0.0–41.0]</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0
(0.0)<break/>[0.0–52.2]</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0
(0.0)<break/>[0.0–60.2]</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">1
(6.3)<break/>[0.2–30.2]</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0
(0.0)<break/>[0.0–20.6]</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">ORR, n
(%)<break/>[95% CI]</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">6
(24.0)<break/>[9.4–45.1]</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">1
(3.8)<break/>[0.1–19.6]</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0
(0.0)<break/>[0.0–20.6]</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0
(0.0)<break/>[0.0–26.5]</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0
(0.0)<break/>[0.0–33.6]</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">1
(20.0)<break/>[0.5–71.6]</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0
(0.0)<break/>[0.0–41.0]</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0
(0.0)<break/>[0.0–52.2]</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0
(0.0)<break/>[0.0–60.2]</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0
(0.0)<break/>[0.0–20.6]</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0
(0.0)<break/>[0.0–20.6]</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">Clinical benefit rate, n
(%)<break/>[95% CI]</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">10
(40.0)<break/>[21.1–61.3]</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">11
(42.3)<break/>[23.4–63.1]</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">3
(18.8)<break/>[4.0–45.6]</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">1
(8.3)<break/>[0.2–38.5]</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">3
(33.3)<break/>[7.5–70.1]</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">3
(60.0)<break/>[14.7–94.7]</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">2
(28.6)<break/>[3.7–71.0]</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">1
(20.0)<break/>[0.5–71.6]</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0
(0.0)<break/>[0.0–60.2]</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">3
(18.8)<break/>[4.0–45.6]</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">2
(12.5)<break/>[1.6–38.3]</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">Median PFS, months</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">3.5</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">5.5</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">1.8</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">1.8</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">2.8</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">20.1</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">2.6</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">1.7</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">2.1</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">1.9</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">1.7</td>
                    </tr>
                  </tbody>
                </table>
              </table-wrap>
              <table-wrap id="T2" position="anchor" orientation="portrait">
                <label>Extended Data Table 2</label>
                <caption>
                  <p id="P39">Treatment-emergent adverse events (occurring in ≥10%
of patients)</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <thead>
                    <tr>
                      <th valign="bottom" rowspan="2" align="left" colspan="1">Adverse event, n
(%)</th>
                      <th colspan="2" valign="bottom" align="center" rowspan="1">Neratinib monotherapy
(N=141) <hr/></th>
                    </tr>
                    <tr>
                      <th valign="bottom" align="center" rowspan="1" colspan="1">Any grade</th>
                      <th valign="bottom" align="center" rowspan="1" colspan="1">Grade ≥3</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">Diarrhoea</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">104 (73.8)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">31 (22.0)*</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">Nausea</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">61 (43.3)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">3 (2.1)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">Vomiting</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">58 (41.1)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">3 (2.1)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">Constipation</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">49 (34.8)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">2 (1.4)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">Fatigue</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">45 (31.9)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">5 (3.5)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">Decreased appetite</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">40 (28.4)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">1 (0.7)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">Abdominal pain</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">33 (23.4)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">7 (5.0)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">Anaemia</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">22 (15.6)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">10 (7.1)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">Dyspnoea</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">18 (12.8)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">5 (3.5)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">Dehydration</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">17 (12.1)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">8 (5.7)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">Aspartate aminotransferase increased</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">15 (10.6)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">5 (3.5)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">Asthenia</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">15 (10.6)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">1 (0.7)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">Weight decreased</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">15 (10.6)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1">0</td>
                    </tr>
                    <tr>
                      <td colspan="3" valign="bottom" align="left" rowspan="1">
                        <hr/>
                      </td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">
                        <bold>Characteristics of
diarrhoea</bold>
                      </td>
                      <td valign="top" align="center" rowspan="1" colspan="1"/>
                      <td valign="top" align="center" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td colspan="3" valign="bottom" align="left" rowspan="1">
                        <hr/>
                      </td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">Action taken with neratinib, n
(%)</td>
                      <td valign="top" align="center" rowspan="1" colspan="1"/>
                      <td valign="top" align="center" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">  Permanent
discontinuation</td>
                      <td colspan="2" valign="top" align="center" rowspan="1">4 (2.8)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">Serious<sup>†</sup> diarrhoea, n
(%)</td>
                      <td colspan="2" valign="top" align="center" rowspan="1">15 (10.6)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">Median (range) number of grade 3 diarrhoea
episodes per patient</td>
                      <td colspan="2" valign="top" align="center" rowspan="1">1 (1–12)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">Median (range) duration of grade 3
diarrhoea episode, days</td>
                      <td colspan="2" valign="top" align="center" rowspan="1">2 (1–8)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">Median (range) time to first grade 3
diarrhoea episode, days</td>
                      <td colspan="2" valign="top" align="center" rowspan="1">10 (4–87)</td>
                    </tr>
                  </tbody>
                </table>
              </table-wrap>
              <table-wrap id="T3" position="anchor" orientation="portrait">
                <label>Extended Data Table 3</label>
                <caption>
                  <p id="P40">PET response criteria CT, computed tomography; FDG-PET,
<sup>18</sup>F-fluorodeoxyglucose positron-emission tomography; SUVmax,
maximum standardised uptake value.</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <thead>
                    <tr>
                      <th valign="top" align="left" rowspan="1" colspan="1">Response category</th>
                      <th valign="top" align="left" rowspan="1" colspan="1">Based on sum of SUV<sub>max</sub> from 1
to 5 target lesions. Each target lesion with initial SUVmax of
&gt;1.5 × normal liver background SUVmax</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">Complete metabolic response (CMR)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">• Reduction of SUVmax of all
target lesions to less than normal liver background SUVmax (for
non-brain lesions) or less than normal brain background SUVmax (for
brain lesions)<break/>AND<break/>• The reduction of all
other FDG-avid lesions consistent with disease to less than normal
liver background SUVmax</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">Partial metabolic response (PMR)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">• Sum of SUV<sub>max</sub> of all
target lesions is decreased by ≥30% compared to
baseline sum of SUVmax of all target
lesions<break/>AND<break/>• No new lesions</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">Stable metabolic disease (SMD)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">Not satisfying the criteria for CMR. PMR.
PMD, or NE</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">Progressive metabolic disease (PMD)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">• Sum of SUV<sub>max</sub>, of all
target lesions is Increased by
≥30%<break/>OR<break/>• Appearance of one or
more unequivocal new FDG avid lesions</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" rowspan="1" colspan="1">Not evaluable (NE)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">• Missing FDG-PET series or
incomplete anatomy at follow-up timepoint<break/>• A PET/CT
scanner change from baseline<break/>• Variation In FDG
uptake time ≥15 minutes compared to
baseline<break/>• Change in reconstruction algorithm</td>
                    </tr>
                  </tbody>
                </table>
              </table-wrap>
              <table-wrap id="T4" position="anchor" orientation="landscape">
                <label>Extended Data Table 4</label>
                <caption>
                  <p id="P41">Patient disposition by cohort NOS, not otherwise specified.</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <thead>
                    <tr>
                      <th valign="bottom" rowspan="3" align="left" colspan="1">Characteristic</th>
                      <th colspan="10" valign="bottom" align="center" rowspan="1">HER2</th>
                      <th valign="bottom" align="center" rowspan="1" colspan="1">HER3</th>
                    </tr>
                    <tr>
                      <th colspan="11" valign="bottom" align="center" rowspan="1">
                        <hr/>
                      </th>
                    </tr>
                    <tr>
                      <th valign="bottom" align="center" rowspan="1" colspan="1">Breast<break/>(n=25)</th>
                      <th valign="bottom" align="center" rowspan="1" colspan="1">Bladder<break/>(n=16)</th>
                      <th valign="bottom" align="center" rowspan="1" colspan="1">Lung<break/>(n=26)</th>
                      <th valign="bottom" align="center" rowspan="1" colspan="1">Colorectal<break/>(n=12)</th>
                      <th valign="bottom" align="center" rowspan="1" colspan="1">Biliary
tract<break/>(n=9)</th>
                      <th valign="bottom" align="center" rowspan="1" colspan="1">Cervical<break/>(n=5)</th>
                      <th valign="bottom" align="center" rowspan="1" colspan="1">Endometrial<break/>(n=7)</th>
                      <th valign="bottom" align="center" rowspan="1" colspan="1">Gastro
esophageal<break/>(n=5)</th>
                      <th valign="bottom" align="center" rowspan="1" colspan="1">Ovarian<break/>(n=4)</th>
                      <th valign="bottom" align="center" rowspan="1" colspan="1">NOS<break/>(n=16)</th>
                      <th valign="bottom" align="center" rowspan="1" colspan="1">NOS<break/>(n=16)</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td valign="bottom" align="left" rowspan="1" colspan="1">Patients continuing on treatment, n
(%)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">1 (4)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">1 (6.2)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">1 (3.8)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">1 (11.1)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">2 (40)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">1 (14.3)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">1 (25)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">2 (12.5)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                    </tr>
                    <tr>
                      <td valign="bottom" align="left" rowspan="1" colspan="1">Treatment discontinuation, n
(%)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">24 (96.0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">15 (93.8)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">25 (96.2)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">12 (100)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">8 (88.9)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">3 (60.0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">6 (85.7)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">5 (100)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">3 (75.0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">14 (87.5)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">16 (100)</td>
                    </tr>
                    <tr>
                      <td valign="bottom" align="left" rowspan="1" colspan="1"> Death</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">1 (6.3)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">1 (11.1)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">1 (6.3)</td>
                    </tr>
                    <tr>
                      <td valign="bottom" align="left" rowspan="1" colspan="1"> Disease progression</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">22 (88.0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">12 (75.0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">18 (69.2)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">11 (91.7)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">5 (55.6)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">2 (40.0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">4 (57.1)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">4 (80.0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">2 (50.0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">9 (56.3)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">15 (93.8)</td>
                    </tr>
                    <tr>
                      <td valign="bottom" align="left" rowspan="1" colspan="1"> Clinical deterioration</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">3 (11.5)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">1 (11.1)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">1 (20.0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">1 (25.0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">2 (12.5)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                    </tr>
                    <tr>
                      <td valign="bottom" align="left" rowspan="1" colspan="1"> Adverse Event</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">2 (7.7)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">1 (11.1)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">1 (14.3)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">1 (6.3)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                    </tr>
                    <tr>
                      <td valign="bottom" align="left" rowspan="1" colspan="1"> Investigator Request</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">1 (6.3)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">1 (8.3)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">1 (14.3)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">2 (12.5)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                    </tr>
                    <tr>
                      <td valign="bottom" align="left" rowspan="1" colspan="1"> Withdrawal of consent</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">2 (8.0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">2 (7.7)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">1 (20.0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                    </tr>
                    <tr>
                      <td valign="bottom" align="left" rowspan="1" colspan="1"> Lost to follow-up</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">1 (6.3)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                    </tr>
                    <tr>
                      <td valign="bottom" align="left" rowspan="1" colspan="1">Subjects ended study, n
(%)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">15 (60.0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">14 (87.5)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">16 (61.5)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">9 (75.0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">6 (66.7)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">1 (20.0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">6 (85.7)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">5 (100)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">3 (75.0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">7 (43.8)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">14 (87.5)</td>
                    </tr>
                    <tr>
                      <td valign="bottom" align="left" rowspan="1" colspan="1"> Death</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">12 (48.0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">13 (81.3)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">13 (50.0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">8 (66.7)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">6 (66.7)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">1 (20.0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">5 (71.4)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">3 (60.0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">3 (75.0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">7 (43.8)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">11 (68.8)</td>
                    </tr>
                    <tr>
                      <td valign="bottom" align="left" rowspan="1" colspan="1"> Withdrawal of consent</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">2 (8.0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">2 (7.7)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">1 (14.3)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">2 (12.5)</td>
                    </tr>
                    <tr>
                      <td valign="bottom" align="left" rowspan="1" colspan="1"> Lost to follow-up</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">1 (4.0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">1 (6.3)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">1 (3.8)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">1 (8.3)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">1 (20.0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">1 (6.3)</td>
                    </tr>
                    <tr>
                      <td valign="bottom" align="left" rowspan="1" colspan="1"> Other</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">1 (20.0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                      <td valign="bottom" align="center" rowspan="1" colspan="1">0 (0)</td>
                    </tr>
                  </tbody>
                </table>
              </table-wrap>
            </sec>
            <sec sec-type="supplementary-material" id="S20">
              <title>Supplementary Material</title>
              <supplementary-material content-type="local-data" id="SD1">
                <label>reporting summary</label>
                <media xlink:href="NIHMS930367-supplement-reporting_summary.pdf" orientation="portrait" xlink:type="simple" id="d36e2490" position="anchor"/>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="S21">
              <p>We thank patients and their families for participating in this study. Editorial
support, not including writing, was provided by Lee Miller of Miller Medical
Communications Ltd, UK. This work was funded by Puma Biotechnology Inc, Los Angeles,
CA, USA.</p>
              <p>
                <bold>Funding support</bold>
              </p>
              <p>Supported by grants from the National Institutes of Health (Grants No. P30 CA008748,
P30 CA016672, P30 CA014089, R01 CA204749, R01 CA80195, T32 CA009207, 1U01 CA180964,
UL1 TR000371), the National Institutes of Health/National Cancer Institute (Breast
SPORE Grant P50 CA098131), Cycle for Survival, Marie-Josée and Henry R.
Kravis Center for Molecular Oncology, The Cancer Prevention and Research Institute
of Texas (RP1100584), the Sheikh Khalifa Bin Zayed Al Nahyan Institute for
Personalized Cancer Therapy, Nellie B. Connally Breast Cancer Research Endowment,
the Breast Cancer Research Foundation, and Puma Biotechnology Inc, Los Angeles, CA,
USA.</p>
            </ack>
            <fn-group>
              <fn id="FN2">
                <p>
                  <bold>Supplementary Information</bold>
                </p>
                <p><xref ref-type="supplementary-material" rid="SD1">Supplementary
Information</xref> is linked to the online version of the paper at <ext-link ext-link-type="uri" xlink:href="www.nature.com/nature">www.nature.com/nature</ext-link>.</p>
              </fn>
              <fn id="FN3" fn-type="con">
                <p>
                  <bold>Author contributions</bold>
                </p>
                <p>D.M.H., H.W., M.F.B., R.E.C, F.X., A.B., L.D.E., G.M., C.F., A.S.L., R.P.B.,
J.B., and D.B.S designed the study and supervised the analyses. R.E.C., F.X.,
L.D.E., G.M., C.F., A.S.L., and R.P.B., helped to collect and monitor the
clinical outcome data. D.M.H., S.A.P., J.R., C.S., G.I.S., D.J., D.I.Q., V.M.,
B.D., I.A.M., V.B., E.C., S.L., A.C.L., J.P.E., B.T.L., A.J.H., R.M., A.M.S.,
A.D., L.M.S., K.J., G.I., J.J.H., C.L.A., F.M.B., J.B., and D.B.D. enrolled
patients and provided patient samples. G.U., developed the PET response criteria
and performed radiographic response assessments. B.S.T., J.P., J.T., S.D.S.,
N.B., M.M., M.F.B., J.B., and D.B.S. performed the tumour and plasma sequencing,
provided computational infrastructure, and made final variant calls. D.M.H.,
H.W., M.S., B.S.T., J.P., J.T., H.B., M.F.B., and D.B.S. analysed clinical and
genomic data and performed the integrated efficacy analyses. F.X. performed
biostatistical analyses of the clinical efficacy data. D.M.H., H.W., B.S.T.,
C.L.A., F.M.B., and D.B.S. wrote the manuscript with input from all authors.</p>
              </fn>
              <fn fn-type="COI-statement" id="FN4">
                <p>Competing financial interests include the following: R.E.C., F.X., L.D.E., G.M.,
C.F., A.S.L., and R.P.B are employees of Puma Biotechnology. D.M.H., M.S., and
J.B. receive research support from Puma Biotechnology, B.T.L. and M.S. receive
research funding from Diachi, A.D. receives personal fees from Roche, and D.S.
received personal fees from Loxo Oncology and Pfizer.</p>
              </fn>
            </fn-group>
            <ref-list>
              <ref id="R1">
                <label>1</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chmielecki</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Oncogenic alterations in <italic>ERBB2/HER2</italic> represent
potential therapeutic targets across tumors from diverse anatomic sites of
origin</article-title>
                  <source>Oncologist</source>
                  <volume>20</volume>
                  <fpage>7</fpage>
                  <lpage>12</lpage>
                  <year>2015</year>
                  <pub-id pub-id-type="pmid">25480824</pub-id>
                </element-citation>
              </ref>
              <ref id="R2">
                <label>2</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Zehir</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Mutational landscape of metastatic cancer revealed from
prospective clinical sequencing of 10,000 patients</article-title>
                  <source>Nat Med</source>
                  <volume>23</volume>
                  <fpage>703</fpage>
                  <lpage>713</lpage>
                  <year>2017</year>
                  <pub-id pub-id-type="pmid">28481359</pub-id>
                </element-citation>
              </ref>
              <ref id="R3">
                <label>3</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Schram</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Landscape of somatic <italic>ERBB2</italic> mutations: Findings
from AACR GENIE and comparison to ongoing <italic>ERBB2</italic> mutant
basket study</article-title>
                  <source>Cancer Res</source>
                  <volume>77</volume>
                  <issue>13 Supplement</issue>
                  <fpage>LB-103</fpage>
                  <year>2017</year>
                </element-citation>
              </ref>
              <ref id="R4">
                <label>4</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chang</surname>
                      <given-names>MT</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Identifying recurrent mutations in cancer reveals widespread
lineage diversity and mutational specificity</article-title>
                  <source>Nat Biotechnol</source>
                  <volume>34</volume>
                  <fpage>155</fpage>
                  <lpage>163</lpage>
                  <year>2016</year>
                  <pub-id pub-id-type="pmid">26619011</pub-id>
                </element-citation>
              </ref>
              <ref id="R5">
                <label>5</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bose</surname>
                      <given-names>R</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Activating <italic>HER2</italic> mutations in
<italic>HER2</italic> gene amplification negative breast
cancer</article-title>
                  <source>Cancer Discov</source>
                  <volume>3</volume>
                  <fpage>224</fpage>
                  <lpage>237</lpage>
                  <year>2013</year>
                  <pub-id pub-id-type="pmid">23220880</pub-id>
                </element-citation>
              </ref>
              <ref id="R6">
                <label>6</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kavuri</surname>
                      <given-names>SM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title><italic>HER2</italic> activating mutations are targets for
colorectal cancer treatment</article-title>
                  <source>Cancer Discov</source>
                  <volume>5</volume>
                  <fpage>832</fpage>
                  <lpage>841</lpage>
                  <year>2015</year>
                  <pub-id pub-id-type="pmid">26243863</pub-id>
                </element-citation>
              </ref>
              <ref id="R7">
                <label>7</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Jaiswal</surname>
                      <given-names>BS</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Oncogenic <italic>ERBB3</italic> mutations in human
cancers</article-title>
                  <source>Cancer Cell</source>
                  <volume>23</volume>
                  <fpage>603</fpage>
                  <lpage>617</lpage>
                  <year>2013</year>
                  <pub-id pub-id-type="pmid">23680147</pub-id>
                </element-citation>
              </ref>
              <ref id="R8">
                <label>8</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chumsri</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Prolonged response to trastuzumab in a patient with
HER2-nonamplified breast cancer with elevated HER2 dimerization harboring an
<italic>ERBB2</italic> S310F Mutation</article-title>
                  <source>J Natl Compr Canc Netw</source>
                  <volume>13</volume>
                  <fpage>1066</fpage>
                  <lpage>1070</lpage>
                  <year>2015</year>
                  <pub-id pub-id-type="pmid">26358791</pub-id>
                </element-citation>
              </ref>
              <ref id="R9">
                <label>9</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Zabransky</surname>
                      <given-names>DJ</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title><italic>HER2</italic> missense mutations have distinct effects on
oncogenic signaling and migration</article-title>
                  <source>Proc Natl Acad Sci USA</source>
                  <volume>112</volume>
                  <fpage>E6205</fpage>
                  <lpage>E6214</lpage>
                  <year>2015</year>
                  <pub-id pub-id-type="pmid">26508629</pub-id>
                </element-citation>
              </ref>
              <ref id="R10">
                <label>10</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hyman</surname>
                      <given-names>DM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Vemurafenib in multiple nonmelanoma cancers with
<italic>BRAF</italic> V600 Mutations</article-title>
                  <source>N Engl J Med</source>
                  <volume>373</volume>
                  <fpage>726</fpage>
                  <lpage>736</lpage>
                  <year>2015</year>
                  <pub-id pub-id-type="pmid">26287849</pub-id>
                </element-citation>
              </ref>
              <ref id="R11">
                <label>11</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hyman</surname>
                      <given-names>DM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>AKT inhibition in solid tumors with AKT1
mutations</article-title>
                  <source>J Clin Oncol</source>
                  <volume>35</volume>
                  <fpage>2251</fpage>
                  <lpage>2259</lpage>
                  <year>2017</year>
                  <pub-id pub-id-type="pmid">28489509</pub-id>
                </element-citation>
              </ref>
              <ref id="R12">
                <label>12</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ross</surname>
                      <given-names>JS</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>A high frequency of activating extracellular domain
<italic>ERBB2</italic> (<italic>HER2</italic>) mutation in
micropapillary urothelial carcinoma</article-title>
                  <source>Clin Cancer Res</source>
                  <volume>20</volume>
                  <fpage>68</fpage>
                  <lpage>75</lpage>
                  <year>2014</year>
                  <pub-id pub-id-type="pmid">24192927</pub-id>
                </element-citation>
              </ref>
              <ref id="R13">
                <label>13</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ross</surname>
                      <given-names>JS</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Relapsed classic E-cadherin (<italic>CDH1</italic>)-mutated
invasive lobular breast cancer shows a high frequency of
<italic>HER2</italic> (<italic>ERBB2</italic>) gene
mutations</article-title>
                  <source>Clin Cancer Res</source>
                  <volume>19</volume>
                  <fpage>2668</fpage>
                  <lpage>2676</lpage>
                  <year>2013</year>
                  <pub-id pub-id-type="pmid">23575477</pub-id>
                </element-citation>
              </ref>
              <ref id="R14">
                <label>14</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wolff</surname>
                      <given-names>AC</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Recommendations for human epidermal growth factor receptor 2
testing in breast cancer: American Society of Clinical Oncology/College of
American Pathologists clinical practice guideline update</article-title>
                  <source>J Clin Oncol</source>
                  <volume>31</volume>
                  <fpage>3997</fpage>
                  <lpage>4013</lpage>
                  <year>2013</year>
                  <pub-id pub-id-type="pmid">24101045</pub-id>
                </element-citation>
              </ref>
              <ref id="R15">
                <label>15</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ma</surname>
                      <given-names>CX</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Neratinib efficacy and circulating tumor DNA detection of HER2
mutations in HER2 non-amplified metastatic breast cancer</article-title>
                  <source>Clin Cancer Res</source>
                  <comment>pii: clincanres.0900.2017</comment>
                  <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-17-0900</pub-id>
                  <year>2017</year>
                </element-citation>
              </ref>
              <ref id="R16">
                <label>16</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yasuda</surname>
                      <given-names>H</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Structural, biochemical, and clinical characterization of
epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung
cancer</article-title>
                  <source>Sci Transl Med</source>
                  <volume>5</volume>
                  <fpage>216ra177</fpage>
                  <year>2013</year>
                </element-citation>
              </ref>
              <ref id="R17">
                <label>17</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Borghaei</surname>
                      <given-names>H</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Nivolumab versus docetaxel in advanced nonsquamous non-small-cell
lung cancer</article-title>
                  <source>N Engl J Med</source>
                  <volume>373</volume>
                  <fpage>1627</fpage>
                  <lpage>1639</lpage>
                  <year>2015</year>
                  <pub-id pub-id-type="pmid">26412456</pub-id>
                </element-citation>
              </ref>
              <ref id="R18">
                <label>18</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kosaka</surname>
                      <given-names>T</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Response heterogeneity of <italic>EGFR</italic> and
<italic>HER2</italic> exon 20 insertions to covalent EGFR and HER2
inhibitors</article-title>
                  <source>Cancer Res</source>
                  <volume>77</volume>
                  <fpage>2712</fpage>
                  <lpage>2721</lpage>
                  <year>2017</year>
                  <pub-id pub-id-type="pmid">28363995</pub-id>
                </element-citation>
              </ref>
              <ref id="R19">
                <label>19</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Freedman</surname>
                      <given-names>RA</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Translational Breast Cancer Research Consortium (TBCRC) 022: A
Phase II trial of neratinib for patients with human epidermal growth factor
receptor 2-positive breast cancer and brain metastases</article-title>
                  <source>J Clin Oncol</source>
                  <volume>34</volume>
                  <fpage>945</fpage>
                  <lpage>952</lpage>
                  <year>2016</year>
                  <pub-id pub-id-type="pmid">26834058</pub-id>
                </element-citation>
              </ref>
              <ref id="R20">
                <label>20</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Shi</surname>
                      <given-names>W</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Pathway level alterations rather than mutations in single genes
predict response to HER2-targeted therapies in the neo-ALTTO
trial</article-title>
                  <source>Ann Oncol</source>
                  <volume>28</volume>
                  <fpage>128</fpage>
                  <lpage>135</lpage>
                  <year>2017</year>
                  <pub-id pub-id-type="pmid">28177460</pub-id>
                </element-citation>
              </ref>
              <ref id="R21">
                <label>21</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Loibl</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title><italic>PIK3CA</italic> mutations are associated with reduced
pathological complete response rates in primary HER2-positive breast cancer:
pooled analysis of 967 patients from five prospective trials investigating
lapatinib and trastuzumab</article-title>
                  <source>Ann Oncol</source>
                  <volume>27</volume>
                  <fpage>1519</fpage>
                  <lpage>1525</lpage>
                  <year>2016</year>
                  <pub-id pub-id-type="pmid">27177864</pub-id>
                </element-citation>
              </ref>
              <ref id="R22">
                <label>22</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Baselga</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled
study of pertuzumab in human epidermal growth factor receptor 2-positive,
first-line metastatic breast cancer</article-title>
                  <source>J Clin Oncol</source>
                  <volume>32</volume>
                  <fpage>3753</fpage>
                  <lpage>3761</lpage>
                  <year>2014</year>
                  <pub-id pub-id-type="pmid">25332247</pub-id>
                </element-citation>
              </ref>
              <ref id="R23">
                <label>23</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Schram</surname>
                      <given-names>AM</given-names>
                    </name>
                    <name>
                      <surname>Berger</surname>
                      <given-names>MF</given-names>
                    </name>
                    <name>
                      <surname>Hyman</surname>
                      <given-names>DM</given-names>
                    </name>
                  </person-group>
                  <article-title>Precision oncology: Charting a path forward to broader deployment
of genomic profiling</article-title>
                  <source>PLoS Med</source>
                  <volume>14</volume>
                  <fpage>e1002242</fpage>
                  <year>2017</year>
                  <pub-id pub-id-type="pmid">28222135</pub-id>
                </element-citation>
              </ref>
              <ref id="R24">
                <label>24</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hyman</surname>
                      <given-names>DM</given-names>
                    </name>
                    <name>
                      <surname>Taylor</surname>
                      <given-names>BS</given-names>
                    </name>
                    <name>
                      <surname>Baselga</surname>
                      <given-names>J</given-names>
                    </name>
                  </person-group>
                  <article-title>Implementing genome-driven oncology</article-title>
                  <source>Cell</source>
                  <volume>168</volume>
                  <fpage>584</fpage>
                  <lpage>599</lpage>
                  <year>2017</year>
                  <pub-id pub-id-type="pmid">28187282</pub-id>
                </element-citation>
              </ref>
              <ref id="R25">
                <label>25</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Jordan</surname>
                      <given-names>EJ</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Prospective Comprehensive Molecular Characterization of Lung
Adenocarcinomas for Efficient Patient Matching to Approved and Emerging
Therapies</article-title>
                  <source>Cancer Discov</source>
                  <volume>7</volume>
                  <fpage>596</fpage>
                  <lpage>609</lpage>
                  <year>2017</year>
                  <pub-id pub-id-type="pmid">28336552</pub-id>
                </element-citation>
              </ref>
              <ref id="R26">
                <label>26</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Baselga</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Phase II study of weekly intravenous recombinant humanized
anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing
metastatic breast cancer</article-title>
                  <source>J Clin Oncol</source>
                  <volume>14</volume>
                  <fpage>737</fpage>
                  <lpage>744</lpage>
                  <year>1996</year>
                  <pub-id pub-id-type="pmid">8622019</pub-id>
                </element-citation>
              </ref>
              <ref id="R27">
                <label>27</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Vogel</surname>
                      <given-names>CL</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Efficacy and safety of trastuzumab as a single agent in
first-line treatment of HER2-overexpressing metastatic breast
cancer</article-title>
                  <source>J Clin Oncol</source>
                  <volume>20</volume>
                  <fpage>719</fpage>
                  <lpage>726</lpage>
                  <year>2002</year>
                  <pub-id pub-id-type="pmid">11821453</pub-id>
                </element-citation>
              </ref>
              <ref id="R28">
                <label>28</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Slamon</surname>
                      <given-names>DJ</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Use of chemotherapy plus a monoclonal antibody against HER2 for
metastatic breast cancer that overexpresses HER2</article-title>
                  <source>N Engl J Med</source>
                  <volume>344</volume>
                  <fpage>783</fpage>
                  <lpage>792</lpage>
                  <year>2001</year>
                  <pub-id pub-id-type="pmid">11248153</pub-id>
                </element-citation>
              </ref>
              <ref id="R29">
                <label>29</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bang</surname>
                      <given-names>YJ</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Trastuzumab in combination with chemotherapy versus chemotherapy
alone for treatment of HER2-positive advanced gastric or gastro-oesophageal
junction cancer (ToGA): a phase 3, open-label, randomised controlled
trial</article-title>
                  <source>Lancet</source>
                  <volume>376</volume>
                  <fpage>687</fpage>
                  <lpage>697</lpage>
                  <year>2010</year>
                  <pub-id pub-id-type="pmid">20728210</pub-id>
                </element-citation>
              </ref>
              <ref id="R30">
                <label>30</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Swain</surname>
                      <given-names>SM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Pertuzumab, trastuzumab, and docetaxel in HER2-positive
metastatic breast cancer</article-title>
                  <source>N Engl J Med</source>
                  <volume>372</volume>
                  <fpage>724</fpage>
                  <lpage>734</lpage>
                  <year>2015</year>
                  <pub-id pub-id-type="pmid">25693012</pub-id>
                </element-citation>
              </ref>
              <ref id="R31">
                <label>31</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Blackwell</surname>
                      <given-names>KL</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Randomized study of lapatinib alone or in combination with
trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic
breast cancer</article-title>
                  <source>J Clin Oncol</source>
                  <volume>28</volume>
                  <fpage>1124</fpage>
                  <lpage>1130</lpage>
                  <year>2010</year>
                  <pub-id pub-id-type="pmid">20124187</pub-id>
                </element-citation>
              </ref>
              <ref id="R32">
                <label>32</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Baselga</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Lapatinib with trastuzumab for HER2-positive early breast cancer
(NeoALTTO): a randomised, open-label, multicentre, phase 3
trial</article-title>
                  <source>Lancet</source>
                  <volume>379</volume>
                  <fpage>633</fpage>
                  <lpage>640</lpage>
                  <year>2012</year>
                  <pub-id pub-id-type="pmid">22257673</pub-id>
                </element-citation>
              </ref>
              <ref id="R33">
                <label>33</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bertotti</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>A molecularly annotated platform of patient-derived xenografts
(“xenopatients”) identifies HER2 as an effective therapeutic
target in cetuximab-resistant colorectal cancer</article-title>
                  <source>Cancer Discov</source>
                  <volume>1</volume>
                  <fpage>508</fpage>
                  <lpage>523</lpage>
                  <year>2011</year>
                  <pub-id pub-id-type="pmid">22586653</pub-id>
                </element-citation>
              </ref>
              <ref id="R34">
                <label>34</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sartore-Bianchi</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Dual-targeted therapy with trastuzumab and lapatinib in
treatment-refractory, <italic>KRAS</italic> codon 12/13 wild-type,
HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept,
multicentre, open-label, phase 2 trial</article-title>
                  <source>Lancet Oncol</source>
                  <volume>17</volume>
                  <fpage>738</fpage>
                  <lpage>746</lpage>
                  <year>2016</year>
                  <pub-id pub-id-type="pmid">27108243</pub-id>
                </element-citation>
              </ref>
              <ref id="R35">
                <label>35</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kaufman</surname>
                      <given-names>B</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Olaparib monotherapy in patients with advanced cancer and a
germline <italic>BRCA1/2</italic> mutation</article-title>
                  <source>J Clin Oncol</source>
                  <volume>33</volume>
                  <fpage>244</fpage>
                  <lpage>250</lpage>
                  <year>2015</year>
                  <pub-id pub-id-type="pmid">25366685</pub-id>
                </element-citation>
              </ref>
              <ref id="R36">
                <label>36</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Le</surname>
                      <given-names>DT</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Mismatch-repair deficiency predicts response of solid tumors to
PD-1 blockade</article-title>
                  <source>Science</source>
                  <pub-id pub-id-type="doi">10.1126/science.aan6733</pub-id>
                  <year>2017</year>
                </element-citation>
              </ref>
              <ref id="R37">
                <label>37</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hyman</surname>
                      <given-names>DM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>The efficacy of larotrectinib (LOXO-101), a selective tropomyosin
receptor kinase (TRK) inhibitor, in adult and pediatric <italic>TRK</italic>
fusion cancers</article-title>
                  <source>J Clin Oncol</source>
                  <volume>35</volume>
                  <issue>suppl</issue>
                  <comment>abstr LBA2501</comment>
                  <year>2017</year>
                </element-citation>
              </ref>
              <ref id="R38">
                <label>38</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wahl</surname>
                      <given-names>RL</given-names>
                    </name>
                    <name>
                      <surname>Jacene</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Kasamon</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Lodge</surname>
                      <given-names>MA</given-names>
                    </name>
                  </person-group>
                  <article-title>From RECIST to PERCIST: Evolving considerations for PET response
criteria in solid tumors</article-title>
                  <source>J Nucl Med</source>
                  <volume>50</volume>
                  <issue>Suppl. 1</issue>
                  <fpage>122S</fpage>
                  <lpage>150S</lpage>
                  <year>2009</year>
                  <pub-id pub-id-type="pmid">19403881</pub-id>
                </element-citation>
              </ref>
              <ref id="R39">
                <label>39</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Zehir</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Mutational landscape of metastatic cancer revealed from
prospective clinical sequencing of 10,000 patients</article-title>
                  <source>Nat Med</source>
                  <volume>23</volume>
                  <fpage>703</fpage>
                  <lpage>713</lpage>
                  <year>2017</year>
                  <pub-id pub-id-type="pmid">28481359</pub-id>
                </element-citation>
              </ref>
              <ref id="R40">
                <label>40</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cheng</surname>
                      <given-names>DT</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Memorial Sloan Kettering-Integrated Mutation Profiling of
Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based
Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular
Oncology</article-title>
                  <source>J Mol Diagn</source>
                  <volume>17</volume>
                  <fpage>251</fpage>
                  <lpage>64</lpage>
                  <year>2015</year>
                  <pub-id pub-id-type="pmid">25801821</pub-id>
                </element-citation>
              </ref>
              <ref id="R41">
                <label>41</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chang</surname>
                      <given-names>MT</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Identifying recurrent mutations in cancer reveals widespread
lineage diversity and mutational specificity</article-title>
                  <source>Nat Biotechnol</source>
                  <volume>34</volume>
                  <fpage>155</fpage>
                  <lpage>63</lpage>
                  <year>2016</year>
                  <pub-id pub-id-type="pmid">26619011</pub-id>
                </element-citation>
              </ref>
              <ref id="R42">
                <label>42</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chang</surname>
                      <given-names>MT</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Accelerating discovery of functional mutant alleles in
cancer</article-title>
                  <source>Cancer Discov</source>
                  <comment>In press</comment>
                </element-citation>
              </ref>
              <ref id="R43">
                <label>43</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kanehisa</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Goto</surname>
                      <given-names>S</given-names>
                    </name>
                  </person-group>
                  <article-title>KEGG: kyoto encyclopedia of genes and genomes</article-title>
                  <source>Nucleic Acids Res</source>
                  <volume>28</volume>
                  <fpage>27</fpage>
                  <lpage>30</lpage>
                  <year>2000</year>
                  <pub-id pub-id-type="pmid">10592173</pub-id>
                </element-citation>
              </ref>
              <ref id="R44">
                <label>44</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chakravarty</surname>
                      <given-names>D</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>OncoKB: A Precision Oncology Knowledge Base</article-title>
                  <source>JCO Precis Oncol</source>
                  <month>7</month>
                  <year>2017</year>
                </element-citation>
              </ref>
              <ref id="R45">
                <label>45</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Shen</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Seshan</surname>
                      <given-names>VE</given-names>
                    </name>
                  </person-group>
                  <article-title>FACETS: allele-specific copy number and clonal heterogeneity
analysis tool for high-throughput DNA sequencing</article-title>
                  <source>Nucleic Acids Res</source>
                  <volume>44</volume>
                  <fpage>e131</fpage>
                  <year>2016</year>
                  <pub-id pub-id-type="pmid">27270079</pub-id>
                </element-citation>
              </ref>
              <ref id="R46">
                <label>46</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Carter</surname>
                      <given-names>SL</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Absolute quantification of somatic DNA alterations in human
cancer</article-title>
                  <source>Nat Biotechnol</source>
                  <volume>30</volume>
                  <fpage>413</fpage>
                  <lpage>21</lpage>
                  <year>2012</year>
                  <pub-id pub-id-type="pmid">22544022</pub-id>
                </element-citation>
              </ref>
              <ref id="R47">
                <label>47</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>McGranahan</surname>
                      <given-names>N</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Clonal status of actionable driver events and the timing of
mutational processes in cancer evolution</article-title>
                  <source>Sci Transl Med</source>
                  <volume>7</volume>
                  <fpage>283ra54</fpage>
                  <year>2015</year>
                </element-citation>
              </ref>
              <ref id="R48">
                <label>48</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Niu</surname>
                      <given-names>B</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>MSIsensor: microsatellite instability detection using paired
tumor-normal sequence data</article-title>
                  <source>Bioinformatics</source>
                  <volume>30</volume>
                  <fpage>1015</fpage>
                  <lpage>6</lpage>
                  <year>2014</year>
                  <pub-id pub-id-type="pmid">24371154</pub-id>
                </element-citation>
              </ref>
              <ref id="R49">
                <label>49</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Alexandrov</surname>
                      <given-names>LB</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Signatures of mutational processes in human
cancer</article-title>
                  <source>Nature</source>
                  <volume>500</volume>
                  <fpage>415</fpage>
                  <lpage>21</lpage>
                  <year>2013</year>
                  <pub-id pub-id-type="pmid">23945592</pub-id>
                </element-citation>
              </ref>
              <ref id="R50">
                <label>50</label>
                <note>
                  <p>Middha <italic>et al</italic>. submitted JCO</p>
                </note>
              </ref>
              <ref id="R51">
                <label>51</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Zhou</surname>
                      <given-names>X</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Exploring genomic alteration in pediatric cancer using
ProteinPaint</article-title>
                  <source>Nat Genetics</source>
                  <volume>48</volume>
                  <fpage>4</fpage>
                  <lpage>6</lpage>
                  <year>2016</year>
                  <pub-id pub-id-type="pmid">26711108</pub-id>
                </element-citation>
              </ref>
            </ref-list>
          </back>
          <floats-group>
            <fig id="F7" orientation="portrait" position="float">
              <label>Figure 1</label>
              <caption>
                <title>Individual treatment outcome and response for 141 patients grouped by a)
tumour cohort and b) mutant allele/domain</title>
                <p>For each panel: The top graph shows percent best change from baseline in the
target lesion assessed by the appropriate response criteria (RECIST version 1.1
or PET). Each bar is colour coded according to its a) mutation allele/domain or
b) tumour type. The middle section shows best overall response. The bottom graph
shows PFS colour coded by treatment status.</p>
                <p>*Non-evaluable.</p>
                <p>Cerv, cervical; endo, endometrial; gastro, gastroesophageal; Ov, ovarian; PET,
positron-emission tomography; PFS, progression-free survival; RECIST, Response
Evaluation Criteria in Solid Tumors.</p>
              </caption>
              <graphic xlink:href="nihms930367f7"/>
            </fig>
            <fig id="F8" orientation="portrait" position="float">
              <label>Figure 2</label>
              <caption>
                <title>Integrated efficacy by tumour type and HER2 allele/domain</title>
                <p>The y-axis represents the ten tumour types and the x-axis represents the mutated
allele/domain and hotspot status. The hotspot mutations are further broken down
into the various domains. The size of the circle is proportional to the
frequency of the tumour type and allele/domain; the colour of the circle
reflects the median percent best change in the target lesion (any positive
median change is indicated in white). The stacked bars represent the best
overall change for the tumour type or domain/allele, as indicated in the
legend.</p>
                <p>ECD, extracellular domain; ICD, intracellular domain; TMB, transmembrane
domain.</p>
              </caption>
              <graphic xlink:href="nihms930367f8"/>
            </fig>
            <fig id="F9" orientation="portrait" position="float">
              <label>Figure 3</label>
              <caption>
                <title>Genomic modifiers of response and outcome by treatment duration</title>
                <p>a) Comprehensive OncoPrint of the dichotomous clinical benefit groups for 86
patients with broad profiling data (left: no benefit (n=66, biologically
independent samples), right: clinical benefit (n=20, biologically
independent samples)). From top to bottom: TMB with the dotted line indicating
the threshold for high TMB at 13.8 mutations per megabase, MSI status,
allele/domain, tumour type, HER2 (<italic>ERBB2</italic>) status showing
amplification, clonality and multiple mutations, and co-alterations in genes
associated with key pathways. *Nominal Fisher’s p-values
unadjusted for multiple hypothesis testing shown. Statistical significance is
lost when corrected for multiple hypothesis testing.</p>
                <p>MSI, microsatellite instability; TMB, tumour mutational burden.</p>
              </caption>
              <graphic xlink:href="nihms930367f9"/>
            </fig>
            <table-wrap id="T5" position="float" orientation="portrait">
              <label>Table 1</label>
              <caption>
                <p>Patient demographics</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th valign="bottom" align="left" rowspan="1" colspan="1">Patient characteristic</th>
                    <th valign="bottom" align="center" rowspan="1" colspan="1">HER2 mutant (n=125)</th>
                    <th valign="bottom" align="center" rowspan="1" colspan="1">HER3 mutant (n=16)</th>
                    <th valign="bottom" align="center" rowspan="1" colspan="1">Total (n=141)</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td valign="top" align="left" rowspan="1" colspan="1">
                      <bold>Age</bold>
                    </td>
                    <td valign="top" align="center" rowspan="1" colspan="1"/>
                    <td valign="top" align="center" rowspan="1" colspan="1"/>
                    <td valign="top" align="center" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td valign="top" align="left" rowspan="1" colspan="1"> Median (range), years</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">61 (30–83)</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">66 (39–82)</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">61 (30–83)</td>
                  </tr>
                  <tr>
                    <td valign="top" align="left" rowspan="1" colspan="1"> &lt;65 years, n (%)</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">81 (64.8)</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">7 (43.8)</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">88 (62.4)</td>
                  </tr>
                  <tr>
                    <td valign="top" align="left" rowspan="1" colspan="1"> ≥65 years, n (%)</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">44 (35.2)</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">9 (56.3)</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">53 (37.6)</td>
                  </tr>
                  <tr>
                    <td valign="top" align="left" rowspan="1" colspan="1">
                      <bold>Sex, n (%)</bold>
                    </td>
                    <td valign="top" align="center" rowspan="1" colspan="1"/>
                    <td valign="top" align="center" rowspan="1" colspan="1"/>
                    <td valign="top" align="center" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td valign="top" align="left" rowspan="1" colspan="1"> Female</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">80 (64.0)</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">12 (75.0)</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">92 (65.2)</td>
                  </tr>
                  <tr>
                    <td valign="top" align="left" rowspan="1" colspan="1"> Male</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">45 (36.0)</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">4 (25.0)</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">49 (34.8)</td>
                  </tr>
                  <tr>
                    <td valign="top" align="left" rowspan="1" colspan="1">
                      <bold>ECOG performance status, n
(%)</bold>
                    </td>
                    <td valign="top" align="center" rowspan="1" colspan="1"/>
                    <td valign="top" align="center" rowspan="1" colspan="1"/>
                    <td valign="top" align="center" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td valign="top" align="left" rowspan="1" colspan="1"> 0</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">37 (29.6)</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">1 (6.3)</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">38 (27.0)</td>
                  </tr>
                  <tr>
                    <td valign="top" align="left" rowspan="1" colspan="1"> 1</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">83 (66.4)</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">12 (75.0)</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">95 (67.4)</td>
                  </tr>
                  <tr>
                    <td valign="top" align="left" rowspan="1" colspan="1"> 2</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">5 (4.0)</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">3 (18.8)</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">8 (5.7)</td>
                  </tr>
                  <tr>
                    <td valign="top" align="left" rowspan="1" colspan="1">
                      <bold>Prior systemic treatment lines, n
(%)</bold>
                    </td>
                    <td valign="top" align="center" rowspan="1" colspan="1"/>
                    <td valign="top" align="center" rowspan="1" colspan="1"/>
                    <td valign="top" align="center" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td valign="top" align="left" rowspan="1" colspan="1"> Any</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">121 (96.8)</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">16 (100)</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">137 (97.2)</td>
                  </tr>
                  <tr>
                    <td valign="top" align="left" rowspan="1" colspan="1"> 1</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">33 (26.4)</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">1 (6.3)</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">34 (24.1)</td>
                  </tr>
                  <tr>
                    <td valign="top" align="left" rowspan="1" colspan="1"> 2</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">30 (24.0)</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">11 (68.8)</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">41 (29.1)</td>
                  </tr>
                  <tr>
                    <td valign="top" align="left" rowspan="1" colspan="1"> ≥3</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">58 (46.4)</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">4 (25.0)</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">62 (44.0)</td>
                  </tr>
                  <tr>
                    <td valign="top" align="left" rowspan="1" colspan="1">
                      <bold>Median time from metastasis to
enrolment, years (range)</bold>
                    </td>
                    <td valign="top" align="center" rowspan="1" colspan="1">1.02 (0.0–15.0)</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">1.13 (0.3–4.5)</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">1.03 (0.0–15.0)</td>
                  </tr>
                  <tr>
                    <td valign="top" align="left" rowspan="1" colspan="1">
                      <bold>Tumour type, n (%)</bold>
                    </td>
                    <td valign="top" align="center" rowspan="1" colspan="1"/>
                    <td valign="top" align="center" rowspan="1" colspan="1"/>
                    <td valign="top" align="center" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td valign="top" align="left" rowspan="1" colspan="1"> Lung</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">26 (20.8)</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">26 (18.4)</td>
                  </tr>
                  <tr>
                    <td valign="top" align="left" rowspan="1" colspan="1"> Breast</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">25 (20.0)</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">25 (17.7)</td>
                  </tr>
                  <tr>
                    <td valign="top" align="left" rowspan="1" colspan="1"> Bladder</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">16 (12.8)</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">2 (12.5)</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">18 (12.8)</td>
                  </tr>
                  <tr>
                    <td valign="top" align="left" rowspan="1" colspan="1"> Colorectal</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">12 (9.6)</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">5 (31.3)</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">17 (12.1)</td>
                  </tr>
                  <tr>
                    <td valign="top" align="left" rowspan="1" colspan="1"> Biliary tract</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">9 (7.2)</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">2 (12.5)</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">11 (7.8)</td>
                  </tr>
                  <tr>
                    <td valign="top" align="left" rowspan="1" colspan="1"> Endometrial</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">7 (5.6)</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">1 (6.3)</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">8 (5.7)</td>
                  </tr>
                  <tr>
                    <td valign="top" align="left" rowspan="1" colspan="1"> Cervical</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">5 (4.0)</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">5 (3.5)</td>
                  </tr>
                  <tr>
                    <td valign="top" align="left" rowspan="1" colspan="1"> Gastroesophageal</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">5 (4.0)</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">2 (12.5)</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">7 (5.0)</td>
                  </tr>
                  <tr>
                    <td valign="top" align="left" rowspan="1" colspan="1"> Ovarian</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">4 (3.2)</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">1 (6.3)</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">5 (3.5)</td>
                  </tr>
                  <tr>
                    <td valign="top" align="left" rowspan="1" colspan="1"> Other</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">16 (12.8)</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">3 (18.8)</td>
                    <td valign="top" align="center" rowspan="1" colspan="1">19 (13.5)</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="TFN1">
                  <p>ECOG, Eastern Cooperative Oncology Group.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </floats-group>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
